Chapter 10 of the Canadian Tuberculosis Standards: Treatment of active tuberculosis in special populations

Authors and affiliations
Key points
Introduction
People with human immunodeficiency virus
People who have undergone solid organ transplant
People prescribed TNF-alpha inhibitors
People with diabetes
People with chronic kidney disease
People with liver disease
Women who are pregnant and breastfeeding
People over 75 years of age with TB
People with alcohol-use disorder
People who inject drugs
People who smoke tobacco
Drug-drug interactions
Disclosure statement
Funding
References

Authors and affiliations

Ryan Cooper; Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada

Stan Houston; Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada; School of Public Health, University of Alberta, Edmonton, Alberta, Canada

Christine Hughes; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

James C. Johnston; Division of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; TB Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

Key points

The management of tuberculosis (TB) in people with medical co-morbidities, substance-use disorders, advanced age or pregnancy is challenging; consultation with a TB expert is recommended.
Adverse events and treatment interruption are more common in these special populations; close monitoring and additional support is often needed.
Given alterations in TB-drug pharmacokinetics and the potential for severe drug-drug interactions in patients with medical co-morbidities, we recommend consultation with an experienced pharmacist.
TB disease and its treatment have important implications for the management of co-morbid conditions; close collaboration with medical specialists and allied health professionals is often required.
The prolonged course of TB treatment is a useful opportunity to screen for co-morbidity and to facilitate referral and linkage into care.

1. Introduction

Medical co-morbidities, substance use-disorders, advanced age and pregnancy can complicate management of TB.^{Footnote 1}^{Footnote 2} Alterations in immunologic control of TB infection may increase the risk of reactivation and lead to more severe forms of TB disease.^{Footnote 1} Co-morbidity may also lead to slower TB treatment response and higher rates of TB relapse.^{Footnote 1} As a result, extension of TB treatment duration is sometimes required to optimize TB treatment outcomes.

These special populations may also differ in absorption, metabolism and clearance of TB drugs. Thus, special attention to dosing of TB medications is needed and, in some groups, therapeutic drug monitoring is recommended.^{Footnote 3} Increased susceptibility to adverse events in some groups may mandate closer monitoring and support, including for drug-drug interactions and overlapping toxicities.

Finally, there is often a lack of comparative clinical data directly relevant to these special populations, as these groups are often excluded from clinical trials due to concerns over harm.

Given these challenges and limitations in the clinical data, consultation with a TB specialist and an experienced pharmacist is strongly recommended. Furthermore, it is important to initiate close collaboration with the patient's medical and allied health care team throughout the TB treatment course.

Here we review additional considerations in TB management of special populations. For each population we will review the impact on epidemiology, clinical presentation, treatment outcomes and management.

2. People with human immunodeficiency virus

Human immunodeficiency virus (HIV) infection increases the risk of TB disease nearly 100-fold.^{Footnote 4}^{Footnote 5} Among people with HIV and M. tuberculosis coinfection, the annual risk of active TB may be as high as 10 per 100 person years.^{Footnote 5}^{Footnote 6} Antiretroviral therapy (ART) reduces the incidence of active TB substantially, although the incidence remains higher than in people without HIV infection, even after normal CD4+ lymphocyte counts are attained.^{Footnote 7}^{Footnote 8}

The predominant immunologic effect of HIV is to reduce cell-mediated immune function. By reducing the number of T-helper cells, macrophage activation and granuloma formation is impaired, compromising the immunologic containment of latent and new TB infections.^{Footnote 9}

HIV also alters the clinical and radiologic features of TB, which are partly determined by the host response.^{Footnote 10} Extra-pulmonary and disseminated forms of TB are more common in people with HIV infection, especially in those with CD4+ lymphocyte counts below 50 × 10⁶/L, while cavitary lung disease and sputum smear-positive disease is less common.^{Footnote 11} This atypical presentation can contribute to diagnostic delay.

HIV infection also affects TB treatment outcomes. Treatment failure with acquired rifampin mono-resistance has been observed with intermittent treatment regimens in people with HIV, particularly among people with CD4 counts <100 × 10⁶/L.^{Footnote 12}^{Footnote 13} TB recurrence is also more common among people with HIV.^{Footnote 14} When molecular techniques have been used to distinguish between relapse and reinfection in communities with high levels of ongoing transmission, however, the rates of relapse with the original strain have been similar.^{Footnote 15}^{Footnote 16} Mortality is higher among people with both HIV and TB and correlates with the degree of immune suppression.^{Footnote 17} With appropriate anti-TB therapy and timely initiation of ART, however, the difference in outcomes can be attenuated.^{Footnote 16}

There are several special considerations in the management of TB and HIV co-infection, including TB drug malabsorption, potential for profound drug-drug interactions and the avoidance of immune reconstitution inflammatory syndrome.

Recommendation:

We strongly recommend that, due to the profound impact of human immunodeficiency virus (HIV) on patient survival and TB treatment outcomes, all patients with TB be screened for HIV infection (good evidence).

Good practice statement:

Treatment of TB in people with human immunodeficiency virus (HIV) should be guided by a physician with expertise in the management of both diseases or in close collaboration with a physician expert in HIV care. Consultation with an expert pharmacist is also advised.

2.1. TB therapy in people with HIV

The anti-TB regimen choice and duration is the same for people with HIV as for those without HIV, except for the selective use of rifabutin in place of rifampin when necessary to achieve compatibility with the ART regimen (see Table 1).^{Footnote 16}^{Footnote 18}^{Footnote 19}^{Footnote 20}^{Footnote 21}^{Footnote 22}^{Footnote 23}^{Footnote 24}

Table 1. Summary of compatible rifamycin-based anti-tuberculous therapy and antiretroviral regimens (last updated September 2021)
Rifamycin	Anchor drug in antiretroviral regimen	Nucleoside analogue component of anti-retroviral regimen
Rifampin 600 mg daily	Efavirenz 600 mg daily^{Footnote 38}^{Footnote 46} Dolutegravir 50 mg twice daily^{Footnote 41Footnote 43} Raltegravir 800 mg twice daily^{Footnote 42}	No clinically important interactions expected^{Footnote 23}^{Footnote 38}
Rifabutin 150 mg daily	Ritonavir "boosted" protease inhibitor^{Footnote 23}^{Footnote 48}	No clinically important interactions expected^{Footnote 23}^{Footnote 38}
Rifabutin 300 mg daily	Dolutegravir 50 mg daily^{Footnote 45} Raltegravir 400 mg twice daily^{Footnote 42Footnote 49} Rilpivirine 50 mg daily^{Footnote 23} Doravirine 100 mg twice daily^{Footnote 23}	No clinically important interactions expected^{Footnote 23}^{Footnote 38}
Note: Expert consultation is strongly advised when selecting antiretroviral therapy (ART) regimens in people on tuberculosis treatment.

Daily administration of TB drugs throughout the treatment course is recommended, as intermittent therapy is associated with worse treatment outcomes, including treatment failure, relapse and acquired drug resistance.^{Footnote 16}^{Footnote 25} Treatment duration is not extended on the basis of HIV co-infection alone. However, in the uncommon scenario where a patient declines to take ART, TB treatment should be extended to 9 months.^{Footnote 16}^{Footnote 21}

Several studies have found that a substantial proportion of people with both HIV and TB infection have low serum concentrations of anti-tuberculous agents.^{Footnote 26}^{Footnote 27}^{Footnote 28}^{Footnote 29}^{Footnote 30}^{Footnote 31} This is thought to be due to a combination of factors, including drug interactions with ART and decreased absorption related to gastrointestinal dysfunction associated with HIV infection.^{Footnote 32} Low serum drug concentrations have been linked to slower response to TB treatment^{Footnote 21}^{Footnote 29}^{Footnote 33}^{Footnote 34} and acquired rifamycin resistance.^{Footnote 35} Thus, we frequently monitor serum drug concentrations in individuals with HIV co-infection to optimize dosing.

HIV-infected individuals are already at increased risk of neuropathy related to HIV and ART. Therefore, in those taking isoniazid (INH), vitamin B6 supplementation is routinely used prevent additional neurologic toxicity from INH-associated neuropathy.

Recommendations:

We strongly recommend a rifamycin (rifampin or rifabutin)-containing regimen for treatment of TB, despite the potential for drug-interactions with antiretroviral therapy (good evidence).
We strongly recommend that TB treatment in human immunodeficiency virus co-infected individuals be administered daily throughout (good evidence).
We conditionally recommend that, if a patient is not taking antiretroviral therapy, TB treatment be extended to 9 months (poor evidence).
We conditionally recommend that, where available, serum TB drug concentrations be measured in people with human immunodeficiency virus co-infection and used to optimize TB drug dosing (poor evidence).

2.2. Antiretroviral therapy in people with HIV and TB

ART is strongly recommended for all people with HIV who also have TB.^{Footnote 23} The optimal timing of ART initiation in people receiving TB treatment, balancing the risk of progressive HIV and TB disease with the risk of immune reconstitution inflammatory syndrome (IRIS), has been evaluated in nine randomized-controlled trials.^{Footnote 36}^{Footnote 37}^{Footnote 38} Two systematic reviews of these trials concluded that early initiation of ART, within 2 weeks of TB therapy initiation, reduces overall mortality and the incidence of additional acquired immunodeficiency syndrome (AIDS)-defining illnesses. The benefit of early initiation of ART was most apparent in patients with CD4 counts of <50 × 10⁶/L.

As an important caveat, early initiation of ART in cases of central nervous system (CNS) TB may be hazardous, probably because of the unique risks of IRIS reactions in the closed space of the cranium. One randomized study of TB meningitis compared immediate ART with a 2-month delay in ART initiation and found higher rates of severe adverse effects in the immediate ART group. However, the mortality rate, which was more than 50%, did not differ between arms.^{Footnote 39} Thus, in those with CNS-TB, the optimal time to initiate ART is not well-established. Delaying therapy at least 2 weeks after initiation of TB treatment appears to provide the best balance between avoiding cerebral complications of IRIS and improved TB treatment outcomes (see Chapter 7: Extra-pulmonary tuberculosis).

In patients already receiving effective combination ART at the time of the TB diagnosis, ART should be continued. However, a change in ART regimen may be required to accommodate potential drug interactions with rifamycins. Note that when an ART dose adjustment is made to address an interaction with a rifamycin, the increased dose should be maintained for 2 weeks after stopping the rifamycin to allow for the liver enzyme induction effect to wear off.

Recommendations:

We strongly recommend initiating antiretroviral therapy within 2 weeks of starting TB therapy, provided there is no documented central nervous system TB (good evidence).
We conditionally recommend delaying antiretroviral therapy (ART) initiation for at least 2 weeks after initiation of anti-TB treatment for those with central nervous system TB, although here the optimal time to initiate ART is less well-established and expert consultation is advised (poor evidence).

2.3. Specific antiretroviral regimens in patients taking Rifamycin-containing TB treatment

Rifamycins are the only anti-tuberculous agents to exert clinically important interactions with antiretroviral drugs (see Table 1). Rifabutin is associated with weaker enzyme induction and thus has less potential for serious drug-drug interactions than either rifapentine or rifampin. However, there is less published clinical experience with rifabutin in the treatment of people with both HIV and TB, and rifampin is usually preferred in this population.^{Footnote 23}^{Footnote 38}

Since rifamycin-based TB treatment is strongly recommended in people with HIV and TB (see recommendation in section 2.1), these drug-drug interactions substantially limit the number of compatible ART regimens available. Current recommendations from the World Health Organization (WHO) for people newly diagnosed with HIV and on treatment for TB is dose-adjusted dolutegravir plus 2 nucleoside analogues. An acceptable alternative is efavirenz plus 2 nucleoside analogues (see Table 1 for dosing for both regimens).^{Footnote 38}

The management of drug-drug interactions between ART and the rifamycin class is an area of active research and recommendations change frequently. Consultation with an experienced pharmacist and a regularly updated clinical drug-interaction resource is prudent (see section 13 on drug-drug interactions).

It is crucial that, while on TB treatment, ongoing monitoring of antiretroviral efficacy is performed. ART efficacy can be compromised in people with HIV and TB co-infection because of drug-drug interactions, reduced adherence related to increased pill burden or overlapping toxicity. Thus, we strongly advise close monitoring of plasma HIV ribonucleic acid (RNA) in people on TB treatment. Monthly testing is recommended until plasma viral load is no longer detectable and then, at minimum, quarterly testing while on TB treatment.

In patients with a suboptimal virologic response to ART in whom an interaction or decreased absorption is a possible explanation, measurement of serum antiretroviral concentrations should be considered, although clinical evidence to support this strategy is lacking. Adherence to ART should also be optimized and antiviral resistance excluded.

Good practice statement:

Close monitoring of plasma human immunodeficiency virus (HIV) RNA in people on treatment for both TB and HIV is suggested with monthly measurements until plasma HIV RNA is no longer detected, followed by quarterly testing during the course of TB treatment.

2.4. Additional considerations in selecting a compatible antiretroviral regimen for people on TB treatment

There are no significant interactions between the nucleoside analogue class and the rifamycin class and these can be used together without dose adjustment. Tenofovir alafenamide serum concentrations are reduced with rifampin but intracellular concentrations of the active form of the drug appear adequate.^{Footnote 40}

All the other antiretroviral drug classes, including protease inhibitors (PI), non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase inhibitors (INI) and CCR5 receptor blockers, demonstrate major interactions with the rifamycins and caution is required.

Dolutegravir and raltegravir may be used with rifampin, provided doses are increased to account for the enhanced metabolism (see Table 1).^{Footnote 41}^{Footnote 42}^{Footnote 43}^{Footnote 44} It should be noted, however, that twice-daily dosing of some components of an ART regimen adds significant complexity and pill-burden and that this can challenge consistent adherence to ART. In a recent randomized controlled trial involving people with HIV and TB receiving rifampin-based treatment, twice-daily raltegravir was less effective at controlling HIV than an efavirenz-based, once-daily regimen.^{Footnote 41} The difference was largely attributed to reduced adherence to the more complicated ART regimen in the raltegravir arm.^{Footnote 41} Although a single, small phase-one study suggests that dolutegravir can be given once daily with rifabutin, there is less published clinical experience with this regimen.^{Footnote 45} Other members of the integrase-inhibitor class — bictegravir and elvitegravir — cannot be used with the rifamycins.^{Footnote 23}

Extensive experience and a controlled trial has shown that the NNRTI efavirenz at standard dosing of 600 mg/day remains effective when used with rifampin, despite variable reduction in efavirenz serum concentrations.^{Footnote 46} An increase in dose of efavirenz to 800 mg has been used in patients with larger body mass or suboptimal viral suppression. Rilpivirine and doravirine are not compatible with rifampin but with dosage adjustment can be co-administered with rifabutin.^{Footnote 23}

No PI dosing regimen has been found to be safe and effective in combination with rifampin. Rifabutin can be substituted for rifampin in TB treatment to permit the use of PIs but is associated with higher rates of hematologic and ocular toxicity.^{Footnote 20}^{Footnote 47} This is because rifabutin concentrations are increased by concomitant therapy with PIs. There is greater experience with ritonavir than cobicistat "boosting" of PIs.

2.5. Immune-reconstitution inflammatory syndrome

IRIS is a frequent early complication of ART in people with HIV and TB. There are two types of IRIS. The first occurs during TB therapy, after ART initiation, and is known as paradoxical IRIS. The second occurs following ART initiation in patients with unrecognized TB, and is known as unmasking IRIS.^{Footnote 47}^{Footnote 50}^{Footnote 51}

IRIS has been reported with a frequency ranging from 8 to 43%.^{Footnote 52} IRIS usually presents as fever and disease progression at involved sites, for example as enlarging lymph nodes, worsening pulmonary infiltrates on chest radiograph or exacerbation of inflammatory changes at other sites. Mortality attributed to IRIS appears to be uncommon except in cases with CNS involvement. Most affected patients have low initial CD4 cell counts, typically 100 × 10⁶/L or less. Onset has been described between 2 and 40 days after ART initiation.

Diagnosis of IRIS requires exclusion of other possible causes, including treatment failure due to drug resistance or development of a different opportunistic infection.^{Footnote 53}

Treatment of IRIS is not always required, as the condition is self-limited. However, if the symptoms are severe enough to warrant therapy, corticosteroids such as prednisone at doses in the range of 1 mg/kg of body weight, given over four weeks, have been shown effective in a randomized trial.^{Footnote 54} Most people can be managed successfully without interruption of ART or TB treatment and in any case, such interruption will not hasten resolution of IRIS.

A single randomized-controlled study has shown that a short course of prednisone given at the same time as ART initiation can reduce the frequency of symptomatic IRIS without increasing the risk of other opportunistic illness.^{Footnote 55} People who should be considered for this intervention are those at high-risk of paradoxical IRIS, defined by CD4 count less than 100 × 10⁶/L. It is important to ensure that patients are responding to TB therapy prior to using preemptive prednisone and that rifampin resistance is excluded. The presence of Kaposi's sarcoma or active hepatitis B infection are additional contraindications.^{Footnote 55}

Recommendation:

We strongly recommend, in people with HIV responding to TB therapy and who are about to initiate antiretroviral therapy, and whose CD4 count is less than 100 x10⁶, prednisone 40 mg/d for 14 days followed by 20 mg/d for 14 days to reduce the risk of symptomatic immune reconstitution inflammatory syndrome, unless rifampin-resistance, Kaposi's sarcoma, and active hepatitis B infection are present as contraindications (good evidence).

Diagnostic considerations in people with both HIV and TB are discussed in Chapter 3: Diagnosis of TB disease and drug-resistant TB and Chapter 4: Diagnosis of TB infection. Regimens used for treatment of latent TB infection in people with HIV are discussed in the Chapter 6: TB preventive treatment in adults.

3. People who have undergone solid organ transplant

Recipients of solid-organ transplantation have a substantially elevated risk of TB that can range between 4 and 30 times that of the general population.^{Footnote 56} This is a result of the potent impact of anti-rejection medications on host T-cell function and cell-mediated immune response.^{Footnote 57} Most commonly, TB in this population represents reactivation of latent infection in the recipient. However, transmission of unrecognized infection in the allograft (donor-derived infection) and acquisition of new infection post-transplantation can also occur.

TB in transplant recipients is frequently atypical in its clinical presentation.^{Footnote 58}^{Footnote 59}^{Footnote 60} Disseminated disease is present in up to 15-30% at TB diagnosis and cavitary disease is less frequent in this population.^{Footnote 58}^{Footnote 61} TB often occurs within the first year following organ transplantation, reflecting both reactivation of previous infection and the period of the most intense immune suppression. Donor-derived TB (i.e., TB arising from the transplanted organ) typically presents within three months of organ transplantation.

TB treatment is more difficult and outcomes are worse in solid-organ transplant recipients compared to other populations.^{Footnote 58}^{Footnote 62} Overlapping drug toxicity and drug-drug interactions lead to adverse events in nearly one-third of transplant recipients receiving TB therapy.^{Footnote 58}^{Footnote 63} Graft dysfunction and organ rejection occur more frequently in transplant recipients with TB compared to those without TB; this is related in part to drug-drug interactions reducing the serum concentrations of immune-suppression therapies. Mortality from TB is higher in transplant recipients, with rates up to 20% in modern cohort studies.^{Footnote 58}^{Footnote 63}^{Footnote 64}

Drug-induced liver injury occurs frequently in transplant recipients, with rates especially high in liver recipients. INH can still be included as part of a first-line regimen, provided liver enzymes and liver function are closely monitored. Pyrazinamide (PZA) should be avoided in liver transplant recipients.^{Footnote 59}^{Footnote 63}^{Footnote 65}

Despite potential for drug-interactions, most experts recommend rifamycin-based for treatment of TB in transplant recipients.^{Footnote 60}^{Footnote 65}^{Footnote 66}^{Footnote 67} However, interactions between TB and immunosuppressive agents necessitates close collaboration with transplant physicians and pharmacists.^{Footnote 60}^{Footnote 66}

Rifabutin, which exerts less potent drug-interactions than rifampin, is the preferred rifamycin for treatment of active TB in this population.^{Footnote 68}^{Footnote 69} The efficacy of rifabutin against TB has been demonstrated in clinical trials (albeit in non-transplant recipients) and is considered comparable to rifampin^{Footnote 20}^{Footnote 70}^{Footnote 71}^{Footnote 72}^{Footnote 73} (see Chapter 5: Treatment of tuberculosis disease). Importantly, rifabutin use appears to lessen the risk of graft rejection in transplant recipients.^{Footnote 70} Regular therapeutic drug monitoring of anti-rejection medications is recommended while on a rifamycin-containing TB treatment.

Dose reduction of immune suppression in transplant recipients is not needed to achieve cure of TB when using rifamycin-based TB treatment regimens. Furthermore, aggressive dose reduction of anti-rejection medications could potentially lead to an inflammatory immune-reconstitution syndrome that in some cases can be severe or life-threatening.^{Footnote 74}

Mold-active azoles (e.g., voriconazole, posaconazole) are used as prophylaxis against fungal infection in some transplant recipients. Serum concentrations of these agents are substantially reduced by rifamycins. There is also a bi-directional interaction with rifabutin, which risks potential rifabutin toxicity. In some centers, azole prophylaxis is avoided.

Therapeutic drug monitoring of anti-TB drugs is also commonly performed in recipients of solid-organ transplants, due to the potential for altered pharmacokinetics in these complicated populations.

TB drugs for solid-organ transplant recipients should be administered daily throughout the treatment course and these patients should be provided with directly observed therapy (DOT) and/or close supportive care. Treatment extension to nine months is endorsed for this population but direct evidence to support this is lacking.^{Footnote 67}^{Footnote 75} Many experts recommend longer treatment courses in transplant recipients, reasoning that, as in untreated HIV infection, where there is also persistent cell-mediated immune dysfunction, treatment extension has been demonstrated in controlled trials to reduce relapse risk.^{Footnote 16}

Recommendations:

We strongly recommend rifamycin-based therapy for optimal treatment of TB in solid-organ transplant recipients (good evidence).
We conditionally recommend rifabutin over rifampin to reduce the risk of potentially severe drug interactions with anti-rejection medications (poor evidence).
We conditionally recommend, given the potentially severe risk of drug-drug interactions, regular therapeutic drug monitoring of anti-rejection medications (poor evidence).
We conditionally recommend treatment extension to nine months for solid-organ transplant recipients (poor evidence).

4. People prescribed TNF-alpha inhibitors

TNF-alpha inhibitors (TNFi), including infliximab, adalimumab, etanercept, golimumab and certrolizumab, are associated with an elevated risk of reactivation of TB disease. Multiple registry analyses estimate the risk of TB to be more than twice that of patients with inflammatory disease not taking TNFi and up to 20 times higher than the general population.^{Footnote 76}^{Footnote 77}^{Footnote 78}^{Footnote 79}

TB reactivation rates appear higher when TNFi therapy is given along with methotrexate or azathioprine.^{Footnote 80} Furthermore, within the TNFi class, infliximab and adalimumab appear to convey a higher risk of TB reactivation than etanercept.^{Footnote 81}^{Footnote 82} The introduction of systematic screening for TB infection prior to initiation of treatment with TNFi appears to have reduced, but not eliminated, TB in people receiving these agents.^{Footnote 79}^{Footnote 83}^{Footnote 84}

TNF-a is a cytokine essential for the activation of macrophages and the formation and maintenance of granulomas.^{Footnote 85} The inhibition of TNF-a function leads to reduced immunologic containment of TB infection and can alter the clinical presentation of disease.

Indeed, people with TNFi-associated TB are more likely to have disseminated, meningeal and extra-pulmonary disease and less likely to have cavitary chest disease or sputum smear positivity.^{Footnote 86}^{Footnote 87} This atypical presentation may delay TB recognition.^{Footnote 87}^{Footnote 88} TB in patients treated with TNFi usually occurs within a median of 3 months after starting TNFi therapy.^{Footnote 87}^{Footnote 89}

Sometimes, use of TNFi is delayed in patients who are under evaluation for possible TB before the diagnosis is confirmed, out of concern that the immune suppression may hasten disease progression or lead to dissemination before effective anti-TB therapy can be established.^{Footnote 90}^{Footnote 91}^{Footnote 92} However, it should be noted that abrupt TNFi withdrawal may be associated with exacerbation of TB disease despite anti-TB treatment, somewhat analogous to IRIS seen in HIV-coinfected patients.^{Footnote 93}^{Footnote 94} Vigilance for this effect is prudent and re-introduction of TNFi has been reportedly effective in its management.^{Footnote 86}^{Footnote 92}^{Footnote 95}^{Footnote 96} Small cohort studies and clinical experience suggest that TNFi can be safely administered once patient is established on effective TB therapy and provided that drug-resistance is not suspected.^{Footnote 95}^{Footnote 97}^{Footnote 98}^{Footnote 99}^{Footnote 100}

Despite lack of experimental data, many experts recommend longer treatment courses in patients receiving TNFi, reasoning that, as for people with untreated HIV infection, and thus persistent immune dysfunction, treatment extension may reduce relapse risk.^{Footnote 16} Relapse in people re-started on TNFi therapy and completing standard TB treatment durations has been reported.^{Footnote 21}^{Footnote 95}

Recommendations:

We conditionally recommend that, where TNF-alpha inhibitors are stopped following the development of TB disease, it can be re-introduced once the patient is established on effective TB therapy (poor evidence).
We conditionally recommend extending TB treatment to nine months in patients receiving TNF-alpha inhibitors (poor evidence).

5. People with diabetes

Systematic reviews have estimated a three-fold increase in active TB in people with diabetes^{Footnote 101}^{Footnote 102} and risk appears especially high in those with poor glycemic control, insulin dependence and higher Hba1c.^{Footnote 103}^{Footnote 104}^{Footnote 105}

The clinical manifestations of TB are altered by the presence of diabetes. Observational studies suggest people with diabetes are more likely to have cavitary and sputum smear-positive disease but less likely to have extra-pulmonary disease.^{Footnote 106}^{Footnote 107}^{Footnote 108}^{Footnote 109}

Hyperglycemia and poorly controlled diabetes have also been correlated with worse TB treatment outcomes. Multiple retrospective studies observe that people with both TB and diabetes experience delayed sputum culture conversion and higher rates of treatment failure, relapse, mortality and acquisition of rifampin resistance.^{Footnote 107}^{Footnote 110}^{Footnote 111}^{Footnote 112}^{Footnote 113}^{Footnote 114}

The prevalence of diabetes in people with newly diagnosed active TB can range up to 25% when routine testing is employed (see Chapter 1: Epidemiology of tuberculosis in Canada, Figure 11). This has been demonstrated in both high TB-incidence and low TB-incidence countries.^{Footnote 115}^{Footnote 116}^{Footnote 117}^{Footnote 118}^{Footnote 119} In one Canadian study, diabetes was present in 19.7% of people with active TB.^{Footnote 120} Thus, screening for diabetes in patients with active TB is recommended and measurement of glycosylated hemoglobin A1C percentage is commonly used.^{Footnote 121}^{Footnote 122}^{Footnote 123}

Good practice statement:

At the time of diagnosis of TB disease, routine screening for diabetes through measurement of glycosylated hemoglobin A1C percentage is suggested and those diagnosed with diabetes should be linked to a diabetes care provider.

Optimization of glycemic control is associated with improved TB treatment outcomes.^{Footnote 109}^{Footnote 111}^{Footnote 124}^{Footnote 125}^{Footnote 126} People diagnosed with diabetes during their TB care should receive a referral to a diabetes care provider for long-term management.

Peak serum TB drug concentrations are frequently low in people with diabetes and this may contribute to the poorer TB treatment outcomes seen in this population.^{Footnote 3}^{Footnote 28}^{Footnote 29}^{Footnote 33}^{Footnote 127} It is not entirely clear how diabetes effects the pharmacokinetics of TB drugs, but increased body weight and gastroparesis with delayed absorption have been suggested as potential factors.^{Footnote 127}^{Footnote 128}^{Footnote 129} At least one observational study has linked the routine measurement of serum TB drug concentrations in diabetic patients with faster microbiological response to TB treatment.^{Footnote 130}

Longer treatment duration may be required in people with diabetes. In one large country-wide registry of people under treatment for pulmonary TB in Taiwan, higher relapse rates seen in people with diabetes was mitigated when TB treatment was extended to 9 months total.^{Footnote 107} However, the impact of treatment extension was small; of 12,688 people with diabetes and TB, relapse rates were 2.23% in those who received 6 months of treatment and 2.00% in those receiving 9 months (aHR 0.75 (95% CI, 0.59-0.97).

Recommendations:

We conditionally recommend that for people with poorly controlled diabetes or evidence of gastroparesis, serum TB drug concentrations be used to optimize drug dosing (poor evidence).
We conditionally recommend treatment extension to 9 months for those with diabetes and cavitary pulmonary or disseminated TB disease (poor evidence).

6. People with chronic kidney disease

End-stage kidney disease requiring dialysis is a well-established risk factor for TB disease, with incidence rates 7 times higher than the general population.^{Footnote 131}^{Footnote 132}^{Footnote 133} Evidence is emerging to suggest that TB risk is also increased in people with earlier stages of chronic kidney disease (CKD), with risk rising as estimated glomerular filtration rate drops below 50 ml/min.^{Footnote 133}^{Footnote 134}^{Footnote 135}

Susceptibility to TB in CKD appears multifactorial.^{Footnote 136}^{Footnote 137} People with CKD often have low 25-hydroxy vitamin D levels and higher rates of protein malnutrition. As uremic waste products accumulate in later stages of renal disease, a broad cellular immune dysfunction develops. The risk of TB may be compounded by associated co-morbid conditions such as diabetes and use of immune suppressive drugs.

The clinical presentation of TB in people with CKD is often insidious and atypical.^{Footnote 136} Systemic symptoms, such as fever, anorexia and weight loss, may mimic uremia and can result in a delay of diagnosis. People with CKD frequently have extra-pulmonary TB, rather than the more recognizable pulmonary disease.^{Footnote 138} Delayed recognition may contribute to the higher mortality rates seen in these populations.^{Footnote 136}

A special consideration in this population is to ensure renal-adjusted dosing for some TB drugs.^{Footnote 136} Rifampin and INH are primarily metabolized and excreted through the liver with little urinary clearance. Thus, dose adjustment of these agents is not required for patients with renal insufficiency.^{Footnote 138} Although PZA is also metabolized primarily through the liver, some of its metabolites are eliminated renally and so its dose should be adjusted in people with advanced CKD (Stage 4/5, GFR < 30ml/min).^{Footnote 138}^{Footnote 139} Ethambutol (EMB) is mostly excreted unchanged by the kidneys and people with advanced CKD have substantially reduced clearance of the drug.^{Footnote 140} Ethambutol-induced ocular toxicity is largely dose-related and so dose adjustment and regular visual acuity testing is necessary in those with advanced CKD.

Because therapeutic efficacy of both PZA and EMB appears dependent on peak concentrations, the dosing interval for both drugs should be extended in people with advanced kidney disease, rather than decreasing the dose administered.

There is insufficient evidence to guide dosing of people with moderate kidney disease (GFR 30-60mL/min). In this range, people should be monitored carefully for toxicity, and therapeutic drug monitoring might be necessary to guide appropriate dosing.

The mechanism of drug removal by peritoneal dialysis is not the same as by hemodialysis and so TB drug-dosing recommendations for people receiving hemodialysis may not necessarily apply. There is comparatively little clinical experience in TB drug-dose adjustment in people receiving peritoneal dialysis.^{Footnote 141}^{Footnote 142} Thus, people receiving peritoneal dialysis should be monitored carefully for drug toxicity and therapeutic drug monitoring may be necessary.

Treatment extension solely based on CKD is not recommended, as neither slower response to treatment nor higher relapse rates have been reported in these patients.

Recommendation:

We conditionally recommend, in people with advanced chronic kidney disease (Stage 4/5, GFR < 30ml/min), that dose intervals should be modified to three times weekly for pyrazinamide (25-30 mg/kg) and ethambutol (15-20 mg/kg) (poor evidence).

Good practice statement:

Pyrazinamide and ethambutol (and other first-line TB drugs) should be dosed after dialysis session in people on hemodialysis.

7. People with liver disease

TB treatment in patients with underlying liver cirrhosis is challenging because with limited hepatic functional reserve, they are at particular risk of liver decompensation following drug-induced hepatotoxicity. For patients with liver cirrhosis of any stage, PZA and INH are best avoided^{Footnote 143} and establishing a hepatic-sparing TB regimen in consultation with a TB expert is recommended.

Although rifampin is associated with drug-induced liver injury, the risk is significantly lower than with either INH or PZA.^{Footnote 144} Furthermore, rifampin is considered crucial to achieving relapse-free (or long-term) TB cure. Thus, rifampin is often used in patients with compensated liver cirrhosis (Child-Pugh A) although is usually avoided in those with overt liver decompensation (Child-Pugh B or C).^{Footnote 143} Fluroquinolones, especially levofloxacin, are associated with low rates of hepatotoxicity and are sometimes used in people with decompensated liver cirrhosis.^{Footnote 145}^{Footnote 146}

Serological screening for viral hepatitis infection should be a part of routine testing at the time of TB treatment initiation for all people with TB, regardless of whether liver disease is apparent on initial testing.^{Footnote 147}^{Footnote 148} Viral hepatitis and TB share epidemiologic associations: both hepatitis B (HBV) and C (HCV) are more prevalent in people from Asian and African regions.^{Footnote 149}^{Footnote 150} In Canada, HCV infection is prevalent in people who use drugs, those who are unstably housed and those born before 1965. Viral hepatitis is also a risk factor for drug-induced liver injury during TB treatment.^{Footnote 151}^{Footnote 152}^{Footnote 153}^{Footnote 154}^{Footnote 155}

Observational data has shown that antiviral treatment of active hepatitis B during TB therapy reduces the incidence of subsequent drug-induced liver injury and hospitalization. TB patients found to be seropositive for hepatitis B surface antigen at the time of TB diagnosis should be promptly referred for hepatitis B treatment.^{Footnote 156}

Currently recommended antiviral treatment regimens for chronic hepatitis C infection are considered incompatible with the rifamycin class because of significant drug-interactions.^{Footnote 157} Antiviral therapy for HCV is thus usually deferred until completion of rifamycin-based TB treatment. Collaboration with a hepatitis specialist is recommended.

Recommendation:

We conditionally recommend routine serological screening for viral hepatitis at the time of TB treatment initiation (poor evidence).

Good practice statement:

When initiating active TB therapy in people with liver cirrhosis, consultation with a TB expert is advised. A hepatic-sparing regimen, which might exclude pyrazinamide and isoniazid, may be required.

8. Women who are pregnant and breastfeeding

8.1. TB and pregnancy

Population studies demonstrate an elevated risk of TB in pregnant and postpartum women, with incidence rates nearly twice that of women who are not pregnant.^{Footnote 2}^{Footnote 158}

Pregnancy suppresses T-helper cell-mediated immune function, increasing susceptibility to TB infection and progressive disease.^{Footnote 159}^{Footnote 160} However, immune suppression seen during pregnancy can also mask the symptoms of progressive disease, making recognition more difficult.^{Footnote 161} Furthermore, insidious symptoms of active TB may be attributed to pregnancy itself. Hesitancy to perform chest radiography may further delay diagnosis.^{Footnote 162} After delivery, T-helper cell suppression is immediately reversed and, in some cases, the symptoms of TB disease are exacerbated as a result.^{Footnote 159}

TB in pregnancy is associated with significant morbidity for both woman and their infants.^{Footnote 163}^{Footnote 164} Pregnant women with TB have higher rates of miscarriage, cesarean sections, anemia, pre-term labor and mortality.^{Footnote 165}^{Footnote 166} Infants born to mothers with active TB are more likely to be premature or low birthweight.^{Footnote 165} Thus, referral to an obstetrician for expert prenatal care is recommended for all pregnant women with TB.

Initiation of treatment for active TB in pregnancy should never be deferred, as the benefits of TB treatment greatly outweigh risks to mother and fetus. TB is not by itself an indication for termination of pregnancy. Treatment of TB in pregnant women is largely the same as in nonpregnant women.^{Footnote 162}^{Footnote 167} Treatment failure and relapse are not more common in pregnancy and treatment extension is not necessary.^{Footnote 168}^{Footnote 169} Dose adjustments are not required with advancing gestation as clinically significant changes to pharmacokinetics of the TB drugs have not been demonstrated.^{Footnote 170} Adverse effects from TB drugs, including drug-induced hepatitis, may be more common in pregnant women and careful monitoring is required.^{Footnote 171}

The first-line anti-TB drugs are all categorized as "Category C" by the US Food and Drug Administration. This classification reflects the lack of controlled studies in pregnant women and possible harm to fetus in animal reproductive studies. However, INH, rifampin and EMB have long track records of safety in pregnancy and are considered acceptable for first-line treatment.^{Footnote 167}^{Footnote 172}^{Footnote 173}

Because PZA is not absolutely necessary to cure TB, and because there is a lack of formal studies on the fetal safety of this drug, its inclusion in treatment regimens for pregnant woman is usually decided on a case-by-case basis. To date, no reports of PZA teratogenicity in humans have emerged despite a long history of use^{Footnote 21} and the WHO continues to recommend its use in pregnant women.^{Footnote 174} If PZA is not used, TB treatment is extended to nine months.

Fluroquinolone use in pregnancy has not been associated with adverse pregnancy outcomes.^{Footnote 175} However, larger studies that include pregnant women exposed to longer treatment durations are needed to better establish safety; at the present time. these drugs should be used only if there are no safer alternatives.

There is considerably less experience with second-line TB agents in pregnancy^{Footnote 167} (see Chapter 8: Drug-resistant tuberculosis). Consultation with an expert in multidrug-resistant TB is recommended.

Recommendations:

We strongly recommend using isoniazid, rifampin and ethambutol as initial treatment in pregnant women, as all 3 are considered safe in pregnancy (good evidence).
We conditionally recommend adding pyrazinamide to the regimen in pregnant women with extensive disease, smear-positive pulmonary disease, disseminated TB or intolerance of any of the other first-line drugs (poor evidence).

8.2. TB and breastfeeding

First-line TB drugs achieve only very minimal concentrations in breast milk and toxicity to infants has not been reported. TB transmission via breast milk has not been reported in the chemotherapeutic era.^{Footnote 176}

Good practice statements:

Breastfeeding is to be encouraged in women taking first-line TB therapy.
Pyridoxine supplementation for the breastfeeding infant is not necessary unless the infant is also taking isoniazid.

See Chapter 9: Pediatric tuberculosis for management of the neonate and peripartum periods.

9. People over 75 years of age with TB

In Canadian-born non-Indigenous and foreign-born Canadians, TB incidence rates are highest in those older than 75 years of age.^{Footnote 177} The higher rate of TB in older adults appears to be driven by a combination of higher prevalence of latent infection, increasing frequency of medical co-morbidities and, possibly, waning immunity.^{Footnote 178}

TB disease can be more difficult to recognize in older adults.^{Footnote 179} Chest radiographic patterns are often atypical, with older adults less likely to demonstrate cavitation or upper-lobe predominance of infiltrates. Older adults are also more likely to have smear-negative disease.^{Footnote 180}

Age over 75 years appears to be associated with poorer TB treatment outcomes, including higher mortality rates and lower completion rates.^{Footnote 180}^{Footnote 181} Age over 75 years is also associated with more adverse events, including gastrointestinal upset, rash, drug interactions and drug-induced liver injury.^{Footnote 144}^{Footnote 182}^{Footnote 183}^{Footnote 184}^{Footnote 185} A systematic review demonstrated that the odds of drug-induced liver injury in active TB treatment was 30% higher in older people than in younger people.^{Footnote 185} In older patients with active TB, PZA is the most common cause of adverse events. However, these risks should be balanced with the benefit of PZA in people with high bacillary burden.

Recommendation:

We conditionally recommend the routine use of pyrazinamide be avoided in older adults, particularly in those over 75 years of age (poor evidence).

10. People with alcohol-use disorder

Excessive alcohol use is a well-established risk for TB. A systematic review found that people who drink more than 40 g of alcohol per day or who have a diagnosed alcohol-use disorder are at a 3-fold higher risk of TB disease compared to people with lower alcohol use.^{Footnote 186}^{Footnote 187}^{Footnote 188}

Alcohol likely exerts a direct toxic effect on the cellular immune system, increasing susceptibility to TB.^{Footnote 188} Furthermore, people with alcohol-use disorder experience higher rates of social marginalization, homelessness, micro- and macronutrient deficiency and incarceration, all of which are associated with elevated rates of TB infection and reactivation.^{Footnote 188}

Alcohol-use disorder has been associated with delay in diagnosis of TB and a higher likelihood of sputum-smear positivity at diagnosis.^{Footnote 189}^{Footnote 190}

People with heavy alcohol use have nearly double the risk of treatment failure and have elevated TB-related mortality.^{Footnote 191}^{Footnote 192}^{Footnote 193} These adverse outcomes are only partly explained by loss to follow-up; high rates of adverse events, intermittent nonadherence and severity of initial disease also contribute. In people with alcohol-use disorder, community-based, rather than clinic-based, DOT is preferred.^{Footnote 191}^{Footnote 194}

Good practice statement:

People with an alcohol-use disorder should receive supportive care, including community-based direct observed therapy, to ensure optimal adherence, and should be linked to alcohol counseling and support services while undergoing TB therapy.

11. People who inject drugs

Although precise estimates are not available, people who inject drugs appear to have a higher risk of TB infection and disease than the general population.^{Footnote 195}^{Footnote 196}^{Footnote 197}^{Footnote 198} This susceptibility is likely mediated by several factors, including co-morbid HIV infection, tobacco use and undernutrition, as well as increased risk of exposure related to homelessness and incarceration. The presentation of TB is not evidently altered by injection drug use itself, absent co-morbid, immune-altering conditions.

Injection drug use has been associated with reduced adherence to, and lower rates of, TB treatment completion.^{Footnote 199} However, enhanced adherence supports such as provision of monetary or material treatment incentives, peer support, integration with opiate agonist therapy and DOT can improve adherence to TB treatment and monitoring.^{Footnote 195}^{Footnote 200}^{Footnote 201} Several studies have highlighted that, with adequate adherence support, high treatment completion rates and good outcomes can be achieved in people who inject drugs.^{Footnote 195}^{Footnote 202}^{Footnote 203}

Co-morbid liver disease is common in people who inject drugs and screening for viral hepatitis and close treatment monitoring is prudent.^{Footnote 195}

Rifampin substantially reduces serum concentrations of methadone and buprenorphine, and this can precipitate opiate withdrawal syndrome.^{Footnote 204} Furthermore, once rifampin is stopped, hepatic enzyme induction will wear off, usually over a period of about 2 weeks, and opiate serum concentrations can then increase, risking opiate toxicity. Rifabutin exerts less of an effect on the metabolism of these drugs and is not usually associated with withdrawal symptoms.^{Footnote 205}^{Footnote 206} Hydromorphone does not interact with the rifamycin drug class and dose adjustment is not necessary.

Given these clinically important drug-drug interactions, dosage adjustment of opioid agonist therapy and close monitoring is required throughout TB therapy. It is important that TB treatment providers alert opioid agonist providers prior to initiating rifamycin therapies and that an opiate monitoring strategy is in place. A notification to the opiate prescriber when the rifamycin is soon to stop is also strongly advised.

For patients who may not tolerate any change to opiate-agonist therapy, rifabutin can be substituted for rifampin in the TB treatment regimen.

Good practice statements:

People with drug-use disorders should receive supportive care, including community-based directly observed therapy, to ensure optimal adherence, and should be linked to drug-use counseling and support services while undergoing TB therapy.
In patients receiving treatment for TB with rifamycin-based regimens who are also on opioid agonist therapy, it is important to adjust opioid agonist therapy in close collaboration with provider at both initiation and completion of the TB treatment course.

12. People who smoke tobacco

People who smoke tobacco are at increased risk of TB infection and progression to active TB, likely due to biologic impacts on innate immune responses and social factors related to exposure.^{Footnote 207}^{Footnote 208} Recent systematic reviews estimate the risk of TB disease to be twice as high in people who smoke compared to nonsmokers.^{Footnote 207}^{Footnote 209}

Smoking may also affect the clinical presentation of TB. Large patient registries from Spain and Hong Kong have demonstrated that people who smoke are more likely to have pulmonary disease, lung cavitation and sputum-smear positivity and are more likely to require hospitalization for TB treatment than are nonsmokers with TB.^{Footnote 210}^{Footnote 211}

Smoking is also associated with worse TB treatment outcomes, including a higher risk of recurrence and increased mortality.^{Footnote 211}^{Footnote 212}^{Footnote 213} One cohort study found those who smoke more than 10 cigarettes per day are twice as likely to relapse as those who do not currently smoke.^{Footnote 214} Additionally, TB is associated with an increased incidence of airway disease after treatment completion, which may compound the adverse effects of smoke exposure and existing airway disease.

TB patients are engaged into medical care for several months and have frequent visits with nursing staff, pharmacists and physicians. This represents a good opportunity to offer help in smoking cessation. A systematic review demonstrated that smoking cessation interventions appear effective in people receiving treatment for TB.^{Footnote 215} No controlled trials have examined the impact of smoking cessation interventions affect TB treatment outcomes.^{Footnote 216}

Good practice statements:

People with TB who smoke tobacco should be offered tobacco cessation interventions during TB therapy.
People with pulmonary TB who smoke tobacco should be offered pulmonary function testing at the end of treatment.

13. Drug-drug interactions

A complete medication review with assessment for potential drug interactions and need for dose adjustments of concomitant medications is recommended for all patients at initiation of TB treatment. Any adjustments of doses of these medications should be reconsidered within 2 weeks of stopping TB treatment.^{Footnote 217}^{Footnote 218}^{Footnote 219}

There are several freely available online drug interaction resources that we suggest can be helpful to guide this assessment:

Rifampin is a well-documented potent inducer of hepatic and intestinal cytochrome P450 (CYP) enzymes, as well as the P-glycoprotein (P-gp) transport system. The onset of induction effects is gradual, with maximal effects on metabolizing enzymes and drug transporters by about two weeks. Induction can last for up to 4 weeks after stopping rifampin.^{Footnote 220}

Rifabutin is a less potent inducer of CYP P450 then rifampin. However, unlike rifampin, rifabutin is also a substrate of CYP3A4 and, therefore, can participate in bi-directional interactions, meaning that the metabolism of rifabutin can be altered by other drugs.^{Footnote 68}^{Footnote 221}

Rifapentine, when dosed weekly, exerts less induction of CYP P450 then does rifampin. However, when rifapentine is dosed daily, it appears to have an even greater inductive effect than standard-dosed rifampin.^{Footnote 222} Rifapentine is not a substrate for CYP3A.

Isoniazid is primarily metabolized via N-acetylation and is an inhibitor of several CYP450 isoenzymes. Isoniazid may inhibit the metabolism of concomitant agents, including some antiepileptics or benzodiazepines.^{Footnote 223}^{Footnote 224}

The absorption of quinolones is significantly affected when administered at the same time as antacids and minerals containing multivalent cations, such as aluminum, magnesium or iron. Separating administration times by at least 2 hours is recommended.^{Footnote 21}

EMB and PZA have a low risk of drug-drug interactions.

Good practice statement:

Drug-drug interactions and altered pharmacokinetics of TB drugs are frequently encountered in people with HIV co-infection, organ transplantation, medical co-morbidities, liver disease, renal dysfunction, and advanced age. Consultation with an experienced pharmacist is recommended when treating TB in these populations.

Table 2. Common drug-drug interactions with Rifamycins (last updated Dec 2021)
Drugs/drug classes impacted	Potential mitigation strategy
Anticoagulants Warfarin Apixaban, dabigatran, edoxaban, rivaroxaban	Continue warfarin with frequent INR monitoring while on rifampin and for 4 weeks after stopping rifampin. Alternatively, could change to LMWH injection.^{Footnote 225}^{Footnote 226} Avoid use of direct-acting oral anticoagulants with rifampin. Rifabutin may be used with dabigatran.^{Footnote 227}^{Footnote 228}^{Footnote 229}^{Footnote 230}^{Footnote 231}
Anticonvulsants carbamazepine, phenytoin, lamotrigine	Consult with neurologist to discuss the possibility of using alternative anti-epileptic agent. Levetiracetam is a preferred anticonvulsant when taking rifamycins as there are no clinically relevant interactions. Alternatively, therapeutic drug monitoring of these anti-epileptic agents with subsequent dose adjustment is required.^{Footnote 232}^{Footnote 233}^{Footnote 234}^{Footnote 235}
Antidiabetics agents	More frequent blood glucose monitoring recommended. Potential for decrease in drug concentration of most oral antidiabetic agents in patients on rifamycins and potential for increased blood glucose levels. Dose adjustment of antidiabetic agents may be required,^{Footnote 236}^{Footnote 237}^{Footnote 238}^{Footnote 239}^{Footnote 240}^{Footnote 241}^{Footnote 242}^{Footnote 243} No significant interaction with metformin or insulin.^{Footnote 243}
Antifungals Azoles (itraconazole, fluconazole, posaconazole, voriconazole, isavuconazole)	Subtherapeutic azole concentrations may occur when used with any of the rifamycins.^{Footnote 244}^{Footnote 245}^{Footnote 246}^{Footnote 247}^{Footnote 248}
Antihypertensives	Increased BP monitoring recommended with most antihypertensives. Rifampin has a strong interaction with calcium channel blockers and clinicians may be required to increase dose of the calcium channel blocker or change/add an alternate antihypertensive agent (consult provider). Rifabutin has a less potent interaction as compared to rifampin.^{Footnote 249}^{Footnote 250}^{Footnote 251}^{Footnote 252}
Antiretroviral agents	See Text and Table 1.
Corticosteroids dexamethasone, methylprednisolone, prednisone	Monitor clinical response. May require increase in dose of corticosteroids.^{Footnote 253}^{Footnote 254}^{Footnote 255}
Immunosuppressive agents cyclosporine, tacrolimus	Rifabutin use is preferred over rifampin to minimize impact on concentrations of calcineurin inhibitors and to reduce the risk of allograft rejection. Monitor calcineurin inhibitor concentrations and adjust dose as required.^{Footnote 256}^{Footnote 257}^{Footnote 258}^{Footnote 259}^{Footnote 260}
Levothyroxine	Continue both agents but monitor TSH monthly. May require increase in dose of levothyroxine with rifamycins. Monitor TSH after stopping rifamycins.^{Footnote 261}^{Footnote 262}^{Footnote 263}
Opiate agonist therapy methadone, buprenorphine/naloxone (Suboxone)	Methadone and buprenorphine serum concentrations decrease substantially with rifampin and precipitation of withdrawal symptoms is frequent. May need preemptive OAT regimen dosage adjustment in addition to close monitoring. Discuss OAT with provider.^{Footnote 204}^{Footnote 264}^{Footnote 265} Rifabutin has much less impact on methadone and buprenorphine serum concentrations and is not associated with withdrawal symptoms.^{Footnote 205}^{Footnote 206}
Oral hormonal contraceptive ethinyl estradiol, norethindrone, etc	Add a barrier method of contraception when taking a rifamycin with oral hormonal contraceptives.^{Footnote 266}
Abbreviations: INR, international normalized ratio; LMWH, Low molecular weight heparin; BP, blood pressure; TSH, thyroid-stimulating hormone; OAT, opiate agonist therapy.

Disclosure statement

The Canadian Thoracic Society (CTS) TB Standards editors and authors declared potential conflicts of interest at the time of appointment and these were updated throughout the process in accordance with the CTS Conflict of Interest Disclosure Policy. Individual member conflict of interest statements are posted on the CTS website.

Funding

The 8th edition Canadian Tuberculosis Standards are jointly funded by the CTS and the Public Health Agency of Canada, edited by the CTS and published by the CTS in collaboration with the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. However, it is important to note that the clinical recommendations in the Standards are those of the CTS. The CTS TB Standards editors and authors are accountable to the CTS Respiratory Guidelines Committee (CRGC) and the CTS Board of Directors. The CTS TB Standards editors and authors are functionally and editorially independent from any funding sources and did not receive any direct funding from external sources. The CTS receives unrestricted grants which are combined into a central operating account to facilitate the knowledge translation activities of the CTS Assemblies and its guideline and standards panels. No corporate funders played any role in the collection, review, analysis or interpretation of the scientific literature or in any decisions regarding the recommendations presented in this document.

References

Footnote 1

Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur Respir J. 2011;37(5):1269–1282. doi:10.1183/09031936.00084310.

Return to footnote 1 referrer

Footnote 2

Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps. Clin Infect Dis. 2012;55(11):1532–49. doi:10.1093/cid/cis732.

Return to footnote 2 referrer

Footnote 3

Perumal R, Naidoo K, Naidoo A, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. Int J Tuberc Lung Dis. 2020;24(1):48–64. doi:10.5588/ijtld.19.0025.

Return to footnote 3 referrer

Footnote 4

Wood R, Maartens G, Lombard CJ. Risk Factors for Developing Tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23(1):75–80. doi:10.1097/00126334-200001010-00010.

Return to footnote 4 referrer

Footnote 5

Selwyn PA, Hartel D, Lewis VA, et al. A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. N Engl J Med. 1989;320(9):545–550. doi:10.1056/nejm198903023200901.

Return to footnote 5 referrer

Footnote 6

Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. The Lancet. 1993;342(8866):268–272. doi:10.1016/0140-6736(93)91817-6.

Return to footnote 6 referrer

Footnote 7

Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi:10.1371/journal.pmed.1001270.

Return to footnote 7 referrer

Footnote 8

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in south africa: Comparison with rates in the community. PLoS One. 2012;7(3):e34156–8. doi:10.1371/journal.pone.0034156.

Return to footnote 8 referrer

Footnote 9

Houben RMGJ, Crampin AC, Ndhlovu R, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. International Journal of Tuberculosis and Lung Disease. 2011;15(1):24–31. doi:10.5588/ijtld.11.0115.

Return to footnote 9 referrer

Footnote 10

Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: Implications for TB screening. Thorax. 2011;66(8):669–673. doi:10.1136/thx.2011.160168.

Return to footnote 10 referrer

Footnote 11

Aderaye G, Bruchfeld J, Assefa G, et al. The relationship between disease pattern and disease burden by chest radiography, M. tuberculosis load, and HIV status in patients with pulmonary tuberculosis in Addis Ababa. Infection. 2004;32(6):333–338. doi:10.1007/s15010-004-3089-x.

Return to footnote 11 referrer

Footnote 12

Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clinical Infectious Diseases. 2005;41(1):83–91. doi:10.1086/430377.

Return to footnote 12 referrer

Footnote 13

Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: A comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731–736. doi:10.1086/381675.

Return to footnote 13 referrer

Footnote 14

Comstock GW, Golub JE, Panjabi R. Recurrent tuberculosis and its risk factors: Adequately treated patients are still at high risk. International Journal of Tuberculosis and Lung Disease. 2007;11(8):828–837.

Return to footnote 14 referrer

Footnote 15

Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: A cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–1693. doi:10.1016/S0140-6736(01)06712-5.

Return to footnote 15 referrer

Footnote 16

Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with hiv infection. Clin Infect Dis. 2012;55(8):1154–1163. doi:10.1093/cid/cis630.

Return to footnote 16 referrer

Footnote 17

Haar CH, Cobelens FGJ, Kalisvaart NA, Van Gerven PJHJ, Van Der Have JJ. HIV-related mortality among tuberculosis patients in the Netherlands, 1993-2001. International Journal of Tuberculosis and Lung Disease. 2007;11(9):1038–1041.

Return to footnote 17 referrer

Footnote 18

El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26(5):1148–1158. doi:10.1086/520275.

Return to footnote 18 referrer

Footnote 19

Perriëns JH, St. Louis ME, Mukadi YB, et al. Pulmonary Tuberculosis in HIV-Infected Patients in Zaire — A Controlled Trial of Treatment for Either 6 or 12 Months. N Engl J Med. 1995;332(12):779–785. doi:10.1056/NEJM199503233321204.

Return to footnote 19 referrer

Footnote 20

Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. The Cochrane Database of Systematic Reviews. 2005; (1):22–24. doi:10.1002/14651858.cd005159.

Return to footnote 20 referrer

Footnote 21

Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi:10.1093/cid/ciw376.

Return to footnote 21 referrer

Footnote 22

Bracchi M, van Halsema C, Post F, et al. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med. 2019;20:s2–s83. doi:10.1111/hiv.12748.

Return to footnote 22 referrer

Footnote 23

Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines. Accessed November 1, 2021.

Return to footnote 23 referrer

Footnote 24

Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14(7):563–571. doi:10.1016/S1473-3099(14)70733-9.

Return to footnote 24 referrer

Footnote 25

Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(4):485–493. doi:10.1001/jamainternmed.2018.0141.

Return to footnote 25 referrer

Footnote 26

Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clinical Infectious Diseases. 2005;41(4):461–469. doi:10.1086/431984.

Return to footnote 26 referrer

Footnote 27

Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from botswana. Clin Infect Dis. 2009;48(12):1685–1694. doi:10.1086/599040.

Return to footnote 27 referrer

Footnote 28

Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs. 2014;74(8):839–854. doi:10.1007/s40265-014-0222-8.

Return to footnote 28 referrer

Footnote 29

Babalik A, Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225–229. doi:10.1155/2011/307150.

Return to footnote 29 referrer

Footnote 30

Daskapan A, Idrus LR, Postma MJ, et al. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clin Pharmacokinet. 2019;58(6):747–766. doi:10.1007/s40262-018-0716-8.

Return to footnote 30 referrer

Footnote 31

Kwara A, Enimil A, Gillani FS, et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. J Pediatric Infect Dis Soc. 2016;5(4):356–365. doi:10.1093/jpids/piv035.

Return to footnote 31 referrer

Footnote 32

Märtson AG, Burch G, Ghimire S, Alffenaar JWC, Peloquin CA. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23–39. doi:10.1080/17425255.2021.1836158.

Return to footnote 32 referrer

Footnote 33

Sileshi T, Tadesse E, Makonnen E, Aklillu E. The impact of first-line anti-tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review. Clin Pharmacol. 2021;13:1–12. doi:10.2147/CPAA.S289714.

Return to footnote 33 referrer

Footnote 34

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–1473. doi:10.1093/infdis/jit352.

Return to footnote 34 referrer

Footnote 35

Weiner M, Benator D, Burman W, Tuberculosis Trials Consortium, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40(10):1481–1491. doi:10.1086/429321.

Return to footnote 35 referrer

Footnote 36

Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: A systematic review and meta-analysis. Ann Intern Med. 2015;163(1):32–39. doi:10.7326/M14-2979.

Return to footnote 36 referrer

Footnote 37

Burke RM, Rickman HM, Singh V, et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta‐analysis. J Int AIDS Soc. 2021;24(7):e25772. doi:10.1002/jia2.25772.

Return to footnote 37 referrer

Footnote 38

World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: recommendations for a Public Health Approach. 2021. Geneva, Switzerland. https://www.who.int/publications/i/item/9789240031593. Accessed November 1, 2021.

Return to footnote 38 referrer

Footnote 39

Török ME, Yen NTB, Chau TTH, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–1383. doi:10.1093/cid/cir230.

Return to footnote 39 referrer

Footnote 40

Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–1678. doi:10.1093/jac/dkz068.

Return to footnote 40 referrer

Footnote 41

De Castro N, Marcy O, Chazallon C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. The Lancet Infectious Diseases. 2021;21(6):813–822. doi:10.1016/S1473-3099(20)30869-0.

Return to footnote 41 referrer

Footnote 42

Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–2856. doi:10.1128/AAC.01468-08.

Return to footnote 42 referrer

Footnote 43

Dooley KE, Kaplan R, Mwelase N, International Study of Patients with HIV on Rifampicin ING study group, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clinical Infectious Diseases. 2019;70(4):549–556. doi:10.1093/cid/ciz256.

Return to footnote 43 referrer

Footnote 44

Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202–206. doi:10.1016/j.ijantimicag.2019.04.009.

Return to footnote 44 referrer

Footnote 45

Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–27. doi:10.1097/QAI.0b013e318276cda9.

Return to footnote 45 referrer

Footnote 46

Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 Weeks results. AIDS. 2006;20(1):131–132. doi:10.1097/01.aids.0000196181.18916.9b.

Return to footnote 46 referrer

Footnote 47

Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet Hiv. 2019;6(7):e463–e474. doi:10.1016/S2352-3018(19)30154-7.

Return to footnote 47 referrer

Footnote 48

Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV Aids. 2010;5(1):61–69. doi:10.1097/COH.0b013e3283339309.

Return to footnote 48 referrer

Footnote 49

Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: In vitro/in vivo correlation. J Clin Pharmacol.2011;51(6):943–950. doi:10.1177/0091270010375959.

Return to footnote 49 referrer

Footnote 50

Meintjes G, Lawn SD, Scano F, International Network for the Study of HIV-associated IRIS, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–523. doi:10.1016/S1473-3099(08)70184-1.

Return to footnote 50 referrer

Footnote 51

Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56(3):450–460. doi:10.1093/cid/cis899.

Return to footnote 51 referrer

Footnote 52

Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: A disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2009;199(3):437–444. doi:10.1086/595985.

Return to footnote 52 referrer

Footnote 53

Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009;48(5):667–676. doi:10.1086/596764.

Return to footnote 53 referrer

Footnote 54

Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381–2390. doi:10.1097/QAD.0b013e32833dfc68.

Return to footnote 54 referrer

Footnote 55

Meintjes G, Stek C, Blumenthal L, PredART Trial Team, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med. 2018;379(20):1915–1925. doi:10.1056/nejmoa1800762.

Return to footnote 55 referrer

Footnote 56

Subramanian AK. Mycobacterium tuberculosis in Transplantation. Emerging Transplant Infections: Clinical Challenges and Implications. 2020;:1–16. doi:10.1007/978-3-030-01751-4_15-1.

Return to footnote 56 referrer

Footnote 57

Torre-Cisneros J, Doblas A, Aguado JM, Spanish Network for Research in Infectious Diseases, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the resitra (spanish network of infection in transplantation) cohort. Clin Infect Dis. 2009;48(12):1657–1665. doi:10.1086/599035.

Return to footnote 57 referrer

Footnote 58

Benito N, García-Vázquez E, Horcajada JP, et al. Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: A retrospective matched cohort study. Clinical Microbiology and Infection. 2015;21(7):651–658. doi:10.1016/j.cmi.2015.03.010.

Return to footnote 58 referrer

Footnote 59

Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis. 1998;27(5):1266–1277. doi:10.1086/514993.

Return to footnote 59 referrer

Footnote 60

Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13513. doi:10.1111/ctr.13513.

Return to footnote 60 referrer

Footnote 61

Giacomelli IL, Neto RS, Marchiori E, Pereira M, Hochhegger B. Chest x-ray and chest ct findings in patients diagnosed with pulmonary tuberculosis following solid organ transplantation: A systematic review. J Bras Pneumol. 2018;44(2):161–166. doi:10.1590/s1806-37562017000000459.

Return to footnote 61 referrer

Footnote 62

Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581–587. doi:10.1086/427692.

Return to footnote 62 referrer

Footnote 63

Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases. Clin Transplant. 2018;32(6):e13259. doi:10.1111/ctr.13259.

Return to footnote 63 referrer

Footnote 64

Sun HY, Munoz P, Torre-Cisneros J, et al. Tuberculosis in solid-organ transplant recipients: Disease characteristics and outcomes in the current era. Prog Transplant. 2014;24(1):37–43. doi:10.7182/pit2014398.

Return to footnote 64 referrer

Footnote 65

Aguado J, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in transplant recipients (GESITRA) of the Spanish society of infectious diseases and clinical microbiology. Clin Infect Dis. 2009;48(9):1276–1284. doi:10.1086/597590.

Return to footnote 65 referrer

Footnote 66

Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM. Mycobacterial infections in solid organ transplant recipients. Clinical Microbiology and Infection. 2014;20:89–101. doi:10.1111/1469-0691.12641.

Return to footnote 66 referrer

Footnote 67

Pennington KM, Kennedy CC, Chandra S, et al. Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review. J Clin Tuberc Other Mycobact Dis. 2018;11:37–46. doi:10.1016/j.jctube.2018.04.001.

Return to footnote 67 referrer

Footnote 68

Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12. doi:10.1185/03007995.2012.747952.

Return to footnote 68 referrer

Footnote 69

Hickey MD, Quan DJ, Chin-Hong PV, Roberts JP. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver Transpl. 2013;19(4):457–461. doi:10.1002/lt.23622.

Return to footnote 69 referrer

Footnote 70

López-Montes A, Gallego E, López E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. American Journal of Kidney Diseases. 2004;44(4):e59–63. doi:10.1053/j.ajkd.2004.06.015.[10.1016/S0272-6386(04)00947-3]

Return to footnote 70 referrer

Footnote 71

Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clinical Infectious Diseases. 1996;22(Supplement_1):S50–S54. doi:10.1093/clinids/22.supplement_1.s50.

Return to footnote 71 referrer

Footnote 72

McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154(5):1462–1467. doi:10.1164/ajrccm.154.5.8912765.

Return to footnote 72 referrer

Footnote 73

Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Rifabutin: Where do we stand in 2016? J Antimicrob Chemother. 2016;71(7):1759–1771. doi:10.1093/jac/dkw024.

Return to footnote 73 referrer

Footnote 74

Sun HY, Munoz P, Torre-Cisneros J, et al. Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients. Transplantation. 2013;95(9):1173–1181. doi:10.1097/TP.0b013e31828719c8.

Return to footnote 74 referrer

Footnote 75

Park YS, Choi JY, Cho CH, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Med J. 2004;45(5):865–872. doi:10.3349/ymj.2004.45.5.865.

Return to footnote 75 referrer

Footnote 76

Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: A systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567–8. doi:10.1136/bmjopen-2016-012567.

Return to footnote 76 referrer

Footnote 77

Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol. 2020;39(5):1439–1447. doi:10.1007/s10067-019-04866-x.

Return to footnote 77 referrer

Footnote 78

Dobler CC. Biological agents and tuberculosis: Risk estimates and screening strategies. Int J Rheum Dis. 2015;18(3):264–267. doi:10.1111/1756-185X.12672.

Return to footnote 78 referrer

Footnote 79

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, BIOBADASER Group, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766–1772. doi:10.1002/art.21043.

Return to footnote 79 referrer

Footnote 80

Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Ann Med. 2014;46(7):547–554. doi:10.3109/07853890.2014.941919.

Return to footnote 80 referrer

Footnote 81

Dixon WG, Hyrich KL, Watson KD, BSR Biologics Register, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528. doi:10.1136/ard.2009.118935.

Return to footnote 81 referrer

Footnote 82

Singh JA, Wells GA, Christensen R, Cochrane Musculoskeletal Group, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. The Cochrane Database of Systematic Reviews. 2011;81(2):CD008794. doi:10.1002/14651858.CD008794.pub2.

Return to footnote 82 referrer

Footnote 83

Gómez-Reino JJ, Carmona L, Rodríguez Valverde V, Mola EM, Montero MD, BIOBADASER Group Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–2127. doi:10.1002/art.11137.

Return to footnote 83 referrer

Footnote 84

Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229–2237. doi:10.3899/jrheum.150057.

Return to footnote 84 referrer

Footnote 85

Solovic I, Sester M, Gomez-Reino JJ, Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B, et al. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J. 2010;36(5):1185–1206. doi:10.1183/09031936.00028510.

Return to footnote 85 referrer

Footnote 86

Arend SM, Leyten EMS, Franken WPJ, Huisman EM, Van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007;45(11):1470–1475. doi:10.1086/522993.

Return to footnote 86 referrer

Footnote 87

Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases. 2004;38(9):1261–1265. doi:10.1086/383317.

Return to footnote 87 referrer

Footnote 88

Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39(3):295–299. doi:10.1086/421494.

Return to footnote 88 referrer

Footnote 89

Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med. 2019;40(4):721–739. doi:10.1016/j.ccm.2019.07.003.

Return to footnote 89 referrer

Footnote 90

Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha- California, 2002-2003. MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control. 2004;53(30):683–685. doi:10.1001/jama.292.14.1676.

Return to footnote 90 referrer

Footnote 91

Cantini F, Prignano F, Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic dis- orders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl. 2014;91(0):78–82. doi:10.3899/jrheum.140106.

Return to footnote 91 referrer

Footnote 92

Wallis RS, van Vuuren C, Potgieter S. Adalimumab Treatment of life-threatening tuberculosis. Clin Infect Dis. 2009;48(10):1429–1432. doi:10.1086/598504.

Return to footnote 92 referrer

Footnote 93

Matsumoto T, Tanaka T, Kawase I. Infliximab for Rheumatoid Arthritis in a Patient with Tuberculosis. N Engl J Med. 2006;355(7):740–741. doi:10.1056/nejmc053468.

Return to footnote 93 referrer

Footnote 94

Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40(5):756–759. doi:10.1086/427941.

Return to footnote 94 referrer

Footnote 95

Dobler CC. Biologic Agents and Tuberculosis. Microbiol Spectr. 2016;4(6). doi:10.1128/microbiolspec.TNMI7-0026-2016.

Return to footnote 95 referrer

Footnote 96

Hsu DC, Faldetta KF, Pei L, et al. A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clin Infect Dis. 2016;62(2):258–261. doi:10.1093/cid/civ841.

Return to footnote 96 referrer

Footnote 97

Cho SK, Kim D, Won S, et al. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum. 2017;47(1):102–107. doi:10.1016/j.semarthrit.2017.01.004.

Return to footnote 97 referrer

Footnote 98

Kim HW, Kwon SR, Jung KH, Korean Society of Spondyloarthritis Research, et al. Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A retrospective nationwide registry of the Korean Society of spondyloarthritis research. PLoS One. 2016;11(4):e0153816–14. doi:10.1371/journal.pone.0153816.

Return to footnote 98 referrer

Footnote 99

Kim YJ, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014;53(8):1477–1481. doi:10.1093/rheumatology/keu041.

Return to footnote 99 referrer

Footnote 100

Ozguler Y, Hatemi G, Ugurlu S, et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int. 2016;36(12):1719–1725. doi:10.1007/s00296-016-3575-3.

Return to footnote 100 referrer

Footnote 101

Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152–1101. doi:10.1371/journal.pmed.0050152.

Return to footnote 101 referrer

Footnote 102

Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One. 2017;12(11):e0187967–26. doi:10.1371/journal.pone.0187967.

Return to footnote 102 referrer

Footnote 103

Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–746. doi:10.1016/S1473-3099(09)70282-8.

Return to footnote 103 referrer

Footnote 104

Viney K, Mills T, Harley D. Tuberculosis and diabetes mellitus: A dose-response relationship between the odds of tuberculosis and HbA1c. Int j Tuberc Lung Dis. 2019;23(10):1055–1059. doi:10.5588/ijtld.18.0657.

Return to footnote 104 referrer

Footnote 105

Golub JE, Mok Y, Hong S, Jung KJ, Jee SH, Samet JM. Diabetes mellitus and tuberculosis in Korean adults: Impact on tuberculosis incidence, recurrence and mortality. Int J Tuberc Lung Dis. 2019;23(4):507–513. doi:10.5588/ijtld.18.0103.

Return to footnote 105 referrer

Footnote 106

Leung CC, Yew WW, Mok TYW, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology. 2017;22(6):1225–1232. doi:10.1111/resp.13017.

Return to footnote 106 referrer

Footnote 107

Wang CS, Yang CJ, Chen HC, et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect. 2009;137(2):203–210. doi:10.1017/S0950268808000782.

Return to footnote 107 referrer

Footnote 108

Morris JT, Seaworth BJ, McAllister CK. Pulmonary tuberculosis in diabetics. Chest. 1992;102(2):539–541. doi:10.1378/chest.102.2.539.

Return to footnote 108 referrer

Footnote 109

Park SW, Shin JW, Kim JY, et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2012;31(7):1305–1310. doi:10.1007/s10096-011-1443-3.

Return to footnote 109 referrer

Footnote 110

Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med. 2011;9(1):81. doi:10.1186/1741-7015-9-81.

Return to footnote 110 referrer

Footnote 111

Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated with Diabetes Mellitus during Tuberculosis Treatment. Clin Infect Dis. 2018;66(2):198–205. doi:10.1093/cid/cix819.

Return to footnote 111 referrer

Footnote 112

Huangfu P, Pearson F, Ugarte-Gil C, Critchley J. Diabetes and poor tuberculosis treatment outcomes: Issues and implications in data interpretation and analysis. Int J Tuberc Lung Dis. 2017;21(12):1214–1219. doi:10.5588/ijtld.17.0211.

Return to footnote 112 referrer

Footnote 113

Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. Clin Infect Dis. 2017;65(12):2060–2068. doi:10.1093/cid/cix632.

Return to footnote 113 referrer

Footnote 114

Mave V, Gaikwad S, Barthwal M, et al. Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India. Open Forum Infect Dis. 2021;8(4):ofab097. doi:10.1093/ofid/ofab097.

Return to footnote 114 referrer

Footnote 115

Armstrong LR, Steve Kammerer J, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010-2017. BMJ Open Diabetes Research and Care. 2020;8(1):1–6. doi:10.1136/bmjdrc-2020-001275.

Return to footnote 115 referrer

Footnote 116

Ugarte-Gil C, Alisjahbana B, Riza AL. Diabetes mellitus among pulmonary tuberculosis patients from four TB - endemic countries: the TANDEM study. Clin Infect Dis. 2020;70(5):780–788. doi: 10.1093/cid/ciz284.

Return to footnote 116 referrer

Footnote 117

White LV, Edwards T, Lee N, et al. Patterns and predictors of co-morbidities in Tuberculosis: A cross-sectional study in the Philippines. Sci Rep. 2020;10(1):1–12. doi:10.1038/s41598-020-60942-2.

Return to footnote 117 referrer

Footnote 118

Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One. 2017;12(4):e0175925–25. doi:10.1371/journal.pone.0175925.

Return to footnote 118 referrer

Footnote 119

Segafredo G, Kapur A, Robbiati C, et al. Integrating TB and non-communicable diseases services: Pilot experience of screening for diabetes and hypertension in patients with Tuberculosis in Luanda, Angola. PLoS One. 2019;14(7):e0218052–11. doi:10.1371/journal.pone.0218052.

Return to footnote 119 referrer

Footnote 120

Barss L, Sabur N, Orlikow E, et al. Diabetes Mellitus in adult patients with active tuberculosis in Canada: Presentation and treatment outcomes. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019;3(2):84–90. doi:10.1080/24745332.2018.1507615.

Return to footnote 120 referrer

Footnote 121

Grint D, Alisjhabana B, Ugarte-Gil C, TANDEM consortium, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ. 2018;96(11):738–749. doi:10.2471/BLT.17.206227.

Return to footnote 121 referrer

Footnote 122

Lin Y, Harries AD, Kumar AMV, et al. Management of Diabetes Mellitus-Tuberculosis. International Union against Tuberculosis and Lung Disease. 2019. https://theunion.org/sites/default/files/2020-11/TheUnion_DMTB_Guide.pdf. Accessed November 1, 2021.

Return to footnote 122 referrer

Footnote 123

Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23(7):783–796. doi:10.5588/ijtld.18.0433.

Return to footnote 123 referrer

Footnote 124

Kornfeld H, Singhal A. Enlisting the Host to Fight TB. Chest. 2018;153(6):1292–1293. doi:10.1016/j.chest.2018.01.011.

Return to footnote 124 referrer

Footnote 125

Shewade HD, Jeyashree K, Mahajan P, et al. Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. PLoS One. 2017;12(10):e0186697–17. doi:10.1371/journal.pone.0186697.

Return to footnote 125 referrer

Footnote 126

Yu X, Li L, Xia L, et al. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: A systematic review. BMC Infect Dis. 2019;19(1):859. doi:10.1186/s12879-019-4548-4.

Return to footnote 126 referrer

Footnote 127

Mtabho CM, Semvua HH, Van Den Boogaard J, et al. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother. 2019;74(12):3537–3545. doi:10.1093/jac/dkz368.

Return to footnote 127 referrer

Footnote 128

Alfarisi O, Mave V, Gaikwad S, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother. 2018;62(11):1–14. doi:10.1128/AAC.01383-18.

Return to footnote 128 referrer

Footnote 129

Dekkers BGJ, Akkerman OW, Alffenaar JWC. Role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus comorbidity. Antimicrob Agents Chemother. 2019;63(2):1–7. doi:10.1128/AAC.02074-18.

Return to footnote 129 referrer

Footnote 130

Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis. 2017;17(1):1–8. doi:10.1186/s12879-017-2226-y.

Return to footnote 130 referrer

Footnote 131

Pradhan RP, Katz LA, Nidus BD, Matalon R, Eisinger RP. Tuberculosis in dialyzed patients. JAMA. 1974;229(7):798–800.

Return to footnote 131 referrer

Footnote 132

Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: A nationwide cohort study. PLoS One. 2011;6(12):e29563–6. doi:10.1371/journal.pone.0029563.

Return to footnote 132 referrer

Footnote 133

Park S, Lee S, Kim Y, et al. Association of CKD with incident tuberculosis. CJASN. 2019;14(7):1002–1010. doi:10.2215/CJN.14471218.

Return to footnote 133 referrer

Footnote 134

Cho PJY, Wu CY, Johnston J, Wu MY, Shu CC, Lin HH. Progression of chronic kidney disease and the risk of tuberculosis: An observational cohort study. Int J Tuberc Lung Dis. 2019;23(5):555–562. doi:10.5588/ijtld.18.0225.

Return to footnote 134 referrer

Footnote 135

Yan M, Puyat JH, Shulha HP, Clark EG, Levin A, Johnston JC. Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. Nephrology Dialysis Transplantation. 2021;37(1):197–116. doi:10.1093/ndt/gfab222.

Return to footnote 135 referrer

Footnote 136

Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90(1):34–40. doi:10.1016/j.kint.2016.01.034.

Return to footnote 136 referrer

Footnote 137

Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2012;59(3):356–363. doi:10.1053/j.ajkd.2011.07.012.

Return to footnote 137 referrer

Footnote 138

Milburn H, Ashman N, Davies P, British Thoracic Society Standards of Care C, Joint Tuberculosis C, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–570. doi:10.1136/thx.2009.133173.

Return to footnote 138 referrer

Footnote 139

Stamatakis G, Montes C, Trouvin JH, et al. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol. 1988;30(4):230–234.

Return to footnote 139 referrer

Footnote 140

Varughese A, Brater DC, Benet LZ, Lee CSC. Ethambutol kinetics in patients with impaired renal function. American Review of Respiratory Disease. 1986;134(1):34–38. doi:10.1016/0278-2316(86)90005-8.

Return to footnote 140 referrer

Footnote 141

Ahn C, Oh KH, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. Perit Dial Int. 2003;23(4):362–367. doi:10.1177/089686080302300409

Return to footnote 141 referrer

Footnote 142

Si M, Li H, Chen Y, Peng H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Reports. 2018;2018:bcr-2017-223187–5. doi:10.1136/bcr-2017-223187.

Return to footnote 142 referrer

Footnote 143

Saukkonen JJ, Cohn DL, Jasmer RM, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. doi:10.1164/rccm.200510-1666ST.

Return to footnote 143 referrer

Footnote 144

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477. doi:10.1164/rccm.200206-626OC.

Return to footnote 144 referrer

Footnote 145

Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: A national case-control safety study. Am J Health Syst Pharm. 2014;71(1):37–43. doi:10.2146/ajhp130165.

Return to footnote 145 referrer

Footnote 146

Paterson JM, Mamdani MM, Manno M, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network Fluoroquinolone therapy and idiosyncratic acute liver injury: A population-based study. CMAJ. 2012;184(14):1565–1570. doi:10.1503/cmaj.111823.

Return to footnote 146 referrer

Footnote 147

Shah H, Bilodeau M, Burak KW, Canadian Association for the Study of the Liver, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677–E687. doi:10.1503/cmaj.170453.

Return to footnote 147 referrer

Footnote 148

Coffin CS, Fung SK, Alvarez F, et al. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ. 2018;1(4):156–217. doi:10.3138/canlivj.2018-0008.

Return to footnote 148 referrer

Footnote 149

Chitnis AS, Cheung R, Gish RG, Wong RJ. Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. J Immigrant Minority Health. 2021;23(6):1213–1267. doi:10.1007/s10903-021-01231-6.

Return to footnote 149 referrer

Footnote 150

Nooredinvand HA, Connell DW, Asgheddi M, et al. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol. 2015;21(29):8920–8980. doi:10.3748/wjg.v21.i29.8920.

Return to footnote 150 referrer

Footnote 151

Chua APG, Lim LKY, Gan SH, Chee CBE, Wang YT. The role of chronic viral hepatitis on tuberculosis treatment interruption. Int j Tuberc Lung Dis. 2018;22(12):1486–1494. doi:10.5588/ijtld.18.0195.

Return to footnote 151 referrer

Footnote 152

Chen L, Bao D, Gu L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):1–10. doi:10.1186/s12879-018-3192-8.

Return to footnote 152 referrer

Footnote 153

Kim WS, Lee SS, Lee CM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16(1):1–7. doi:10.1186/s12879-016-1344-2.

Return to footnote 153 referrer

Footnote 154

Zheng J, Guo MH, Peng HW, Cai XL, Wu YL, Peng XE. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: A meta-analysis of cohort studies. Epidemiol Infect. 2020;148:E290. doi:10.1017/S0950268820002861.

Return to footnote 154 referrer

Footnote 155

Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6):1871–1876. doi:10.1164/ajrccm.157.6.9711039.

Return to footnote 155 referrer

Footnote 156

Lui GCY, Wong NS, Wong RYK, et al. Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients with Tuberculosis and Hepatitis B Coinfection. Clin Infect Dis. 2020;70(4):660–666. doi:10.1093/cid/ciz241.

Return to footnote 156 referrer

Footnote 157

Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother. 2019;63(12):1–14. doi:10.1128/AAC.01215-19.

Return to footnote 157 referrer

Footnote 158

Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779–784. doi:10.1164/rccm.201106-1083OC.

Return to footnote 158 referrer

Footnote 159

Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis. 2007;45(9):1192–1199. doi:10.1086/522182.

Return to footnote 159 referrer

Footnote 160

Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and post-partum: a register-based cohort study in Sweden. Eur Respir J. 2020;55(3):1901886. doi:10.1183/13993003.01886-2019.

Return to footnote 160 referrer

Footnote 161

Llewelyn M, Cropley I, Wilkinson RJ, Davidson RN. Tuberculosis diagnosed during pregnancy: a prospective study from London. Thorax. 2000;55(2):129–132. doi:10.1136/thorax.55.2.129.

Return to footnote 161 referrer

Footnote 162

Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol. 2020;135(6):1444–1453. doi:10.1097/AOG.0000000000003890.

Return to footnote 162 referrer

Footnote 163

Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet. Feb. 1994;44(2):119–124. doi:10.1016/0020-7292(94)90064-7.

Return to footnote 163 referrer

Footnote 164

Figueroa-Damian R, Arredondo-Garcia JL. Neonatal outcome of children born to women with tuberculosis. Arch Med Res. 2001;32(1):66–69. doi:10.1016/s0188-4409(00)00266-6.

Return to footnote 164 referrer

Footnote 165

Sobhy S, Babiker Z, Zamora J, Khan KS, Kunst H. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG. 2017;124(5):727–733. doi:10.1111/1471-0528.14408.

Return to footnote 165 referrer

Footnote 166

S KJ, B A, H GK, G SM. Tuberculosis in pregnant women and neonates: A meta-review of current evidence. Paediatr Respir Rev. 2020;36:27–32. doi:10.1016/j.prrv.2020.02.001.

Return to footnote 166 referrer

Footnote 167

Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med. 2019;16(8):e1002882. doi:10.1371/journal.pmed.1002882.

Return to footnote 167 referrer

Footnote 168

Snider D. Pregnancy and Tuberculosis. Chest. 1984;86(3 Suppl):10S–13S. doi:10.1378/chest.86.3.10S.

Return to footnote 168 referrer

Footnote 169

Water BJVD, Brooks MB, Huang C-c, et al. Tuberculosis clinical presentation and treatment outcomes in pregnancy: a prospective cohort study. BMC Infect Dis. 2020;20(1):686. doi:10.1186/s12879-020-05416-6.

Return to footnote 169 referrer

Footnote 170

Abdelwahab MT, Leisegang R, Dooley KE, et al. Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. Antimicrob Agents Chemother. 2020;64(3):e01978–19. doi:10.1128/AAC.01978-19.

Return to footnote 170 referrer

Footnote 171

Gupta A, Montepiedra G, Aaron L, IMPAACT P1078 TB APPRISE Study Team, et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019;381(14):1333–1346. doi:10.1056/nejmoa1813060.

Return to footnote 171 referrer

Footnote 172

Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. Int J Tuberc Lung Dis. 2001;5(6):564–568.

Return to footnote 172 referrer

Footnote 173

Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf. 2001;24(7):553–565. doi:10.2165/00002018-200124070-00006.

Return to footnote 173 referrer

Footnote 174

Treatment of tuberculosis: guidelines, World Health Organization Previous editions had different title: Treatment 2010.

Return to footnote 174 referrer

Footnote 175

Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG: Int J Obstet Gy. 2018; 125(9):1069–1076. doi:10.1111/1471-0528.15119.

Return to footnote 175 referrer

Footnote 176

Pediatrics AAo. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, Illinois: American Academy of Pediatrics; 2018.

Return to footnote 176 referrer

Footnote 177

Gallant V, Duvvuri V, McGuire M. Tuberculosis in Canada - Summary 2015. Can Commun Dis Rep. Mar 2 2017;43(3-4):77–82. doi:10.14745/ccdr.v43i34a04.

Return to footnote 177 referrer

Footnote 178

Hochberg NS, Horsburgh CR.Jr. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis. 2013;56(9):1240–1247. Maydoi:10.1093/cid/cit027.

Return to footnote 178 referrer

Footnote 179

Symes MJ, Probyn B, Daneshvar C, Telisinghe L. Diagnosing Pulmonary Tuberculosis in the Elderly. Curr Geri Rep. 2020;9(2):30–39. doi:10.1007/s13670-020-00319-5.

Return to footnote 179 referrer

Footnote 180

Gardner Toren K, Spitters C, Pecha M, Bhattarai S, Horne DJ, Narita M. Tuberculosis in Older Adults: Seattle and King County, Washington. Clin Infect Dis. 2020;70(6):1202–1207. doi:10.1093/cid/ciz306.

Return to footnote 180 referrer

Footnote 181

Hase I, Toren KG, Hirano H, et al. Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation. Drugs and Aging. 2021;38(9):807–815. doi:10.1007/s40266-021-00880-4.

Return to footnote 181 referrer

Footnote 182

Kwon BS, Kim Y, Lee SH, et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One. 2020;15(7):e0236109–10. doi:10.1371/journal.pone.0236109.

Return to footnote 182 referrer

Footnote 183

Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis. 2007;11(8):868–875.

Return to footnote 183 referrer

Footnote 184

Tweed CD, Wills GH, Crook AM, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018;16(1):46. doi:10.1186/s12916-018-1033-7.

Return to footnote 184 referrer

Footnote 185

Hosford JD, von Fricken ME, Lauzardo M, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95(2):112–122. doi:10.1016/j.tube.2014.10.006.

Return to footnote 185 referrer

Footnote 186

Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - A systematic review. BMC Public Health. 2008;8(1):289. doi:10.1186/1471-2458-8-289.

Return to footnote 186 referrer

Footnote 187

Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: Meta-analyses and burden of disease. Eur Respir J. 2017;50(1):1700216. doi:10.1183/13993003.00216-2017.

Return to footnote 187 referrer

Footnote 188

Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9(1):412–450. doi:10.1186/1471-2458-9-450.

Return to footnote 188 referrer

Footnote 189

Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8(1):15–19. doi:10.1186/1471-2458-8-15.

Return to footnote 189 referrer

Footnote 190

Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Tuberculosis and excess alcohol use in the United States, 1997-2012. Int J Tuberc Lung Dis. 2015;19(1):111–119. doi:10.5588/ijtld.14.0516.

Return to footnote 190 referrer

Footnote 191

Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):73–82. doi:10.5588/ijtld.19.0080.

Return to footnote 191 referrer

Footnote 192

Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: A systematic review and meta-analysis. Sci Rep. 2018;8(1):1–13. doi:10.1038/s41598-018-23344-z.

Return to footnote 192 referrer

Footnote 193

Torres NMC, Rodríguez JJQ, Andrade PSP, Arriaga MB, Netto EM. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PLoS One. 2019;14(12):e0226507–24. doi:10.1371/journal.pone.0226507.

Return to footnote 193 referrer

Footnote 194

Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis: Epidemiology and effect on the outcome of treatment. Chest. 1997;111(5):1168–1173. doi:10.1378/chest.111.5.1168.

Return to footnote 194 referrer

Footnote 195

Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: Review and update. Clin Infect Dis. 2009;48(1):72–82. doi:10.1086/594126.

Return to footnote 195 referrer

Footnote 196

Minja LT, Hella J, Mbwambo J, et al. High burden of tuberculosis infection and disease among people receiving medication-assisted treatment for substance use disorder in Tanzania. PLoS One. 2021;16(4):e0250038. doi:10.1371/journal.pone.0250038.

Return to footnote 196 referrer

Footnote 197

Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: Evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV Aids. 2012;7(4):345–353. doi:10.1097/COH.0b013e328354bd44.

Return to footnote 197 referrer

Footnote 198

Duarte R, Lönnroth K, Carvalho C, et al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018;24(2):115–119. doi:10.1016/j.rppnen.2017.11.003.

Return to footnote 198 referrer

Footnote 199

Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: Predictors and consequences in New York City. American Journal of Medicine. 1997;102(2):164–170. doi:10.1016/S0002-9343(96)00402-0.

Return to footnote 199 referrer

Footnote 200

Chaisson RE, Barnes GL, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. American Journal of Medicine. 2001;110(8):610–615. doi:10.1016/S0002-9343(01)00695-7.

Return to footnote 200 referrer

Footnote 201

Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002;66(3):283–293. doi:10.1016/S0376-8716(01)00208-3.

Return to footnote 201 referrer

Footnote 202

Smirnoff M, Goldberg R, Indyk L, Adler JJ. Directly observed therapy in an inner city hospital. International Journal of Tuberculosis and Lung Disease. 1998;2(2):134–139.

Return to footnote 202 referrer

Footnote 203

Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med. 1995;151(5):1486–1490. doi:10.1164/ajrccm.151.5.7735604.

Return to footnote 203 referrer

Footnote 204

Raistrick D, Hay A, Wolff K. Methadone maintenance and tuberculosis treatment. BMJ. 1996;313(7062):925–926. doi:10.1136/bmj.313.7062.925.

Return to footnote 204 referrer

Footnote 205

McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2-3):326–334. doi:10.1016/j.drugalcdep.2011.04.013.

Return to footnote 205 referrer

Footnote 206

Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend. 1996;43(1-2):71–77. doi:10.1016/S0376-8716(97)84352-9.

Return to footnote 206 referrer

Footnote 207

Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: A systematic review and meta-analysis. Arch Intern Med. 2007;167(4):335–342. doi:10.1001/archinte.167.4.335.

Return to footnote 207 referrer

Footnote 208

Van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: The colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33. doi:10.1183/09031936.00072909.

Return to footnote 208 referrer

Footnote 209

Obore N, Kawuki J, Guan J, Papabathini SS, Wang L. Association between indoor air pollution, tobacco smoke and tuberculosis: an updated systematic review and meta-analysis. Public Health. 2020;187:24–35. doi:10.1016/j.puhe.2020.07.031.

Return to footnote 209 referrer

Footnote 210

Altet-Gómez MN, Alcaide J, Godoy P, Romero MA. Hernández Del Rey I. Clinical and epidemiological aspects of smoking and tuberculosis: A study of 13 038 cases. International Journal of Tuberculosis and Lung Disease. 2005;9(4):430–436.

Return to footnote 210 referrer

Footnote 211

Leung CC, Yew WW, Chan CK, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J. 2015;45(3):738–745. doi:10.1183/09031936.00114214.

Return to footnote 211 referrer

Footnote 212

Burusie A, Enquesilassie F, Addissie A, Dessalegn B, Lamaro T. Effect of smoking on tuberculosis treatment outcomes: A systematic review and meta-analysis. PLoS One. 2020;15(9):e0239333–20. doi:10.1371/journal.pone.0239333.

Return to footnote 212 referrer

Footnote 213

Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: Retrospective study of 43 000 adult male deaths and 35 000 controls. Lancet. 2003;362(9383):507–515. doi:10.1016/S0140-6736(03)14109-8.

Return to footnote 213 referrer

Footnote 214

Yen YF, Yen MY, Lin YS, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: A population-based study. Int J Tuberc Lung Dis. 2014;18(4):492–498. doi:10.5588/ijtld.13.0694.

Return to footnote 214 referrer

Footnote 215

Whitehouse E, Lai J, Golub JE, Farley JE. A systematic review of the effectiveness of smoking cessation interventions among patients with tuberculosis. Public Health Action. 2018;8(2):37–49. doi:10.5588/pha.18.0006.

Return to footnote 215 referrer

Footnote 216

Jeyashree K, Kathirvel S, Shewade HD, Kaur H, Goel S, Cochrane Tobacco Addiction Group. Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. The Cochrane Database of Systematic Reviews. 2016;CD011125. doi:10.1002/14651858.CD011125.pub2.

Return to footnote 216 referrer

Footnote 217

Alffenaar JWC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70(8):1774–1780. doi:10.1093/cid/ciz942.

Return to footnote 217 referrer

Footnote 218

Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(12):1468–1481. doi:10.1592/phco.29.12.1468.

Return to footnote 218 referrer

Footnote 219

Abrogoua DP, Kamenan BAT, Ahui BJM, Doffou E. Pharmaceutical interventions in the management of tuberculosis in a pneumophtisiology department, ivory coast. Ther Clin Risk Manag. 2016;12:1749–1756. doi:10.2147/TCRM.S118442.

Return to footnote 219 referrer

Footnote 220

Reitman ML, Chu X, Cai X, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234–242. doi:10.1038/clpt.2010.271.

Return to footnote 220 referrer

Footnote 221

Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2019;15(8):615–618. doi:10.1080/17425255.2019.1648432.

Return to footnote 221 referrer

Footnote 222

Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):881–888. doi:10.1038/clpt.2011.323.

Return to footnote 222 referrer

Footnote 223

Sahasrabudhe V, Zhu T, Vaz A, Tse S. Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs. J Infect Dis. 2015;211(suppl 3):S107–S114. doi:10.1093/infdis/jiv009.

Return to footnote 223 referrer

Footnote 224

McFeely SJ, Yu J, Zhao P, et al. Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic? Clin Pharmacol Ther. 2019;105(6):1378–1385. doi:10.1002/cpt.1397.

Return to footnote 224 referrer

Footnote 225

Yang CS, Boswell R, Bungard TJ. A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management. Eur J Clin Pharmacol. 2021;77(3):341–348. doi:10.1007/s00228-020-03057-x.

Return to footnote 225 referrer

Footnote 226

Martins MAP, Reis AMM, Sales MF, et al. Rifampicin-warfarin interaction leading to macroscopic hematuria: A case report and review of the literature. BMC Pharmacol Toxicol. 2013;14(1):10–27. doi:10.1186/2050-6511-14-27.

Return to footnote 226 referrer

Footnote 227

Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341–1350. doi:10.1016/j.jacc.2019.12.068.

Return to footnote 227 referrer

Footnote 228

Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191–1198. doi:10.1002/cpt.1072.

Return to footnote 228 referrer

Footnote 229

Chang SH, Chou IJ, Yeh YH, et al. Association between use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA - Journal of the American Medical Association. 2017;318(13):1250–1259. doi:10.1001/jama.2017.13883.

Return to footnote 229 referrer

Footnote 230

Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447–453. doi:10.1007/s40261-015-0298-2.

Return to footnote 230 referrer

Footnote 231

Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor xa. Am J Cardiovasc Drugs. 2016;16(2):119–127. doi:10.1007/s40256-015-0157-9.

Return to footnote 231 referrer

Footnote 232

Kay L, Kampmann J, Svendsen T, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol. 1985;20(4):323–326. doi:10.1111/j.1365-2125.1985.tb05071.x.

Return to footnote 232 referrer

Footnote 233

Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. European Journal of Clinical Pharmacology. 2000;56(4):299–304. doi:10.1007/s002280000146.

Return to footnote 233 referrer

Footnote 234

Wimpelmann J, Høvik H, Riedel B, Slørdal L. The interaction between rifampicin and lamotrigine: A case report. Br J Clin Pharmacol. 2019;85(8):1859–1860. doi:10.1111/bcp.13973.

Return to footnote 234 referrer

Footnote 235

Egelund EF, Mohamed MEF, Fennelly KP, Peloquin CA. Concomitant use of carbamazepine and rifampin in a patient with mycobacterium avium complex and seizure disorder. J Pharm Technol. 2014;30(3):93–96. doi:10.1177/8755122514523934.

Return to footnote 235 referrer

Footnote 236

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br J Clin Pharmacol. 2003;56(4):427–432. doi:10.1046/j.1365-2125.2003.01884.x.

Return to footnote 236 referrer

Footnote 237

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clinical Pharmacology and Therapeutics. 2001;69(6):400–406. doi:10.1067/mcp.2001.115822.

Return to footnote 237 referrer

Footnote 238

Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics. 2004;76(3):239–249. doi:10.1016/j.clpt.2004.05.001.

Return to footnote 238 referrer

Footnote 239

Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003;42(9):819–850. doi:10.2165/00003088-200342090-00003.

Return to footnote 239 referrer

Footnote 240

Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther. 2004;75(3):157–162. doi:10.1016/j.clpt.2003.10.003.

Return to footnote 240 referrer

Footnote 241

Sahi J, Black CB, Hamilton GA, et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003;31(4):439–446. doi:10.1124/dmd.31.4.439.

Return to footnote 241 referrer

Footnote 242

Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. Jan 2006;61(1):70–78. doi:10.1111/j.1365-2125.2005.02515.x.

Return to footnote 242 referrer

Footnote 243

Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740–753. Sep doi:10.1016/S2213-8587(14)70110-X.

Return to footnote 243 referrer

Footnote 244

Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14(1):165–174. doi:10.1093/clinids/14.1.165.

Return to footnote 244 referrer

Footnote 245

Hohmann C, Kang EM, Jancel T. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis. 2010;50(6):939–940. doi:10.1086/650740.

Return to footnote 245 referrer

Footnote 246

Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother. 2007;51(9):3455–3456. doi:10.1128/AAC.00579-07.

Return to footnote 246 referrer

Footnote 247

Townsend R, Dietz A, Hale C, et al. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53. doi:10.1002/cpdd.285.

Return to footnote 247 referrer

Footnote 248

Ayudhya DPN, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet. 2004;43(11):725–732. doi:10.2165/00003088-200443110-00003.

Return to footnote 248 referrer

Footnote 249

Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol. 1986;31(1):59–62. doi:10.1007/BF00870987.

Return to footnote 249 referrer

Footnote 250

Tada Y, Tsuda Y, Otsuka T, et al. Case report: Nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. Am J Med Sci. 1992;303(1):25–27. doi:10.1097/00000441-199201000-00006.

Return to footnote 250 referrer

Footnote 251

Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63(3):316–323. doi:10.1016/S0009-9236(98)90163-1.

Return to footnote 251 referrer

Footnote 252

Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. Pharmacotherapy. 2020;40(4):274–290. doi:10.1002/phar.2380.

Return to footnote 252 referrer

Footnote 253

McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923–925. doi:10.1136/bmj.286.6369.923.

Return to footnote 253 referrer

Footnote 254

Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Respir Dis. 1983;128(2):307–310. doi:10.1164/arrd.1983.128.2.307.

Return to footnote 254 referrer

Footnote 255

Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. Eur J Clin Pharmacol. 1993;45(3):287–289. doi:10.1007/BF00315399.

Return to footnote 255 referrer

Footnote 256

Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc. 2003;35(7):2449–2451. doi:10.1016/j.transproceed.2003.08.019.

Return to footnote 256 referrer

Footnote 257

van Buren D, Wideman CA, Ried M, et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc. 1984;16(6):1642–1645.

Return to footnote 257 referrer

Footnote 258

Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999;39(1):91–96. doi:10.1177/00912709922007499.

Return to footnote 258 referrer

Footnote 259

Wang Y-C, Salvador NG, Lin C-C, et al. Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis. Biomedical Journal. 2020;:1–9. doi:10.1016/j.bj.2020.08.010.

Return to footnote 259 referrer

Footnote 260

Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III. Arch Intern Med. Nov 24 1997;157(21):2453–2458.

Return to footnote 260 referrer

Footnote 261

Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. South Med J. 1999;92(5):529–531. doi:10.1097/00007611-199905000-00018.

Return to footnote 261 referrer

Footnote 262

Kim HI, Kim TH, Kim H, et al. Effect of Rifampin on thyroid function test in patients on levothyroxine medication. PLoS One. 2017;12(1):e0169775–11. doi:10.1371/journal.pone.0169775.

Return to footnote 262 referrer

Footnote 263

Takasu N, Kinjou Y, Kouki T, Takara M, Ohshiro Y, Komiya I. Rifampin-induced hypothyroidism. J Endocrinol Invest. 2006;29(7):645–649. doi:10.1007/BF03344165.

Return to footnote 263 referrer

Footnote 264

Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med. 1976;294(20):1104–1106. doi:10.1056/NEJM197605132942008.

Return to footnote 264 referrer

Footnote 265

Badhan RKS, Gittins R, Al Zabit D. The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. Drug Alcohol Depend. 2019;200:168–180. doi:10.1016/j.drugalcdep.2019.03.013.

Return to footnote 265 referrer

Footnote 266

Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018;125(7):804–811. doi:10.1111/1471-0528.15027.

Return to footnote 266 referrer

Page details

Date modified:: 2025-03-13

Language selection

Search

Chapter 10 of the Canadian Tuberculosis Standards: Treatment of active tuberculosis in special populations

On this page

Authors and affiliations

Key points

1. Introduction

2. People with human immunodeficiency virus

2.1. TB therapy in people with HIV

2.2. Antiretroviral therapy in people with HIV and TB

2.3. Specific antiretroviral regimens in patients taking Rifamycin-containing TB treatment

2.4. Additional considerations in selecting a compatible antiretroviral regimen for people on TB treatment

2.5. Immune-reconstitution inflammatory syndrome

3. People who have undergone solid organ transplant

4. People prescribed TNF-alpha inhibitors

5. People with diabetes

6. People with chronic kidney disease

7. People with liver disease

8. Women who are pregnant and breastfeeding

8.1. TB and pregnancy

8.2. TB and breastfeeding

9. People over 75 years of age with TB

10. People with alcohol-use disorder

11. People who inject drugs

12. People who smoke tobacco

13. Drug-drug interactions

Disclosure statement

Funding

References

Page details